UNITED STATES Washington, D.C. 20549 | OMB APPROVAL | |
OMB Number: 3235-0582 | ||
Expires: July 31, 2024 | ||
Estimated average burden | ||
hours per response........4 |
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811-04889
Tekla Healthcare Investors
(Exact name of registrant as specified in charter)
100 Federal Street, 19th Floor, Boston, MA | 02110 | |
(Address of principal executive offices) | (Zip code) |
Laura Woodward
Tekla Healthcare Investors
100 Federal Street, 19th Floor, Boston MA 02110
(Name and address of agent for service)
Registrant’s telephone number, including area code: 617-772-8500
Date of fiscal year end: September 30
Date of reporting period: 7/1/22-6/30/23
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.
Item 1. Proxy Voting Record.
Vote Summary
ABBOTT LABORATORIES
Security | 002824100 | Meeting Type | Annual |
Ticker Symbol | ABT | Meeting Date | 28-Apr-2023 |
Record Date | 01-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: R. J. Alpern | Management | For | For | |||||
1b. | Election of Director: C. Babineaux-Fontenot | Management | For | For | |||||
1c. | Election of Director: S. E. Blount | Management | For | For | |||||
1d. | Election of Director: R. B. Ford | Management | For | For | |||||
1e. | Election of Director: P. Gonzalez | Management | For | For | |||||
1f. | Election of Director: M. A. Kumbier | Management | For | For | |||||
1g. | Election of Director: D. W. McDew | Management | For | For | |||||
1h. | Election of Director: N. McKinstry | Management | For | For | |||||
1i. | Election of Director: M. G. O'Grady | Management | For | For | |||||
1j. | Election of Director: M. F. Roman | Management | For | For | |||||
1k. | Election of Director: D. J. Starks | Management | For | For | |||||
1l. | Election of Director: J. G. Stratton | Management | For | For | |||||
2. | Ratification of Ernst & Young LLP As Auditors | Management | For | For | |||||
3. | Say on Pay - An Advisory Vote on the Approval of Executive Compensation | Management | For | For | |||||
4. | Say When on Pay - An Advisory Vote on the Approval of the Frequency of Shareholder Votes on Executive Compensation | Management | 1 Year | For | |||||
5. | Shareholder Proposal - Special Shareholder Meeting Threshold | Shareholder | Against | For | |||||
6. | Shareholder Proposal - Independent Board Chairman | Shareholder | Against | For | |||||
7. | Shareholder Proposal - Lobbying Disclosure | Shareholder | Against | For | |||||
8. | Shareholder Proposal - Incentive Compensation | Shareholder | Against | For |
ABBVIE INC.
Security | 00287Y109 | Meeting Type | Annual |
Ticker Symbol | ABBV | Meeting Date | 05-May-2023 |
Record Date | 06-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class II Director: Robert J. Alpern | Management | For | For | |||||
1b. | Election of Class II Director: Melody B. Meyer | Management | For | For | |||||
1c. | Election of Class II Director: Frederick H. Waddell | Management | For | For | |||||
2. | Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2023. | Management | For | For | |||||
3. | Say on Pay - An advisory vote on the approval of executive compensation. | Management | For | For | |||||
4. | Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting. | Management | For | For | |||||
5. | Stockholder Proposal - to Implement Simple Majority Vote. | Shareholder | Against | For | |||||
6. | Stockholder Proposal - to Issue an Annual Report on Political Spending. | Shareholder | Against | For | |||||
7. | Stockholder Proposal - to Issue an Annual Report on Lobbying. | Shareholder | Against | For | |||||
8. | Stockholder Proposal - to Issue a Report on Patent Process. | Shareholder | Against | For |
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Security | 00650F109 | Meeting Type | Annual |
Ticker Symbol | ADPT | Meeting Date | 09-Jun-2023 |
Record Date | 12-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Katey Owen, PhD | Management | For | For | |||||
1.2 | To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Robert Hershberg, PhD, MD | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For |
AFFIMED N.V
Security | N01045108 | Meeting Type | Annual |
Ticker Symbol | AFMD | Meeting Date | 21-Jun-2023 |
Record Date | 24-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
3. | Adoption of the Statutory Annual Accounts for the financial year 2022 | Management | For | For | |||||
4. | Advisory vote (non-binding) on Executive Compensation | Management | For | For | |||||
5. | Discharge of the managing directors for their management during the financial year 2022 | Management | For | For | |||||
6. | Discharge of the supervisory directors for their supervision during the financial year 2022 | Management | For | For | |||||
7. | Amendment of the Remuneration Policy for the Supervisory Board | Management | For | For | |||||
8a. | Reappointment of Dr. Adi Hoess as a managing director | Management | For | For | |||||
8b. | Reappointment of Dr. Wolfgang Fischer as a managing director | Management | For | For | |||||
8c. | Reappointment of Mr. Angus Smith as a managing director | Management | For | For | |||||
8d. | Reappointment of Dr. Arndt Schottelius as a managing director | Management | For | For | |||||
8e. | Reappointment of Dr. Andreas Harstrick as a managing director | Management | For | For | |||||
9a. | Reappointment of Dr. Thomas Hecht as a supervisory director | Management | For | For | |||||
9b. | Reappointment of Mr. Harry Welten as a supervisory director | Management | For | For | |||||
9c. | Reappointment of Dr. Annalisa M. Jenkins as a supervisory director | Management | For | For | |||||
9d. | Appointment of Dr. Constanze Ulmer-Eilfort as a supervisory director | Management | For | For | |||||
10. | Reverse stock split and amendment of the articles of association | Management | For | For | |||||
11. | Authorization to acquire shares | Management | For | For | |||||
12. | Appointment of the auditor for the financial year 2023 | Management | For | For |
ALKERMES PLC
Security | G01767105 | Meeting Type | Contested-Annual |
Ticker Symbol | ALKS | Meeting Date | 29-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | BOARD NOMINEE: Emily Peterson Alva | Management | For | For | |||||
1B. | BOARD NOMINEE: Shane M. Cooke | Management | For | For | |||||
1C. | BOARD NOMINEE: Richard B. Gaynor, M.D. | Management | For | For | |||||
1D. | BOARD NOMINEE: Cato T. Laurencin, M.D., Ph.D. | Management | For | For | |||||
1E. | BOARD NOMINEE: Brian P. McKeon | Management | For | For | |||||
1F. | BOARD NOMINEE: Richard F. Pops | Management | For | For | |||||
1G. | BOARD NOMINEE: Christopher I. Wright, M.D., Ph.D. | Management | For | For | |||||
1H. | SARISSA NOMINEE: Patrice Bonfiglio | Management | Withheld | For | |||||
1I. | SARISSA NOMINEE: Alexander Denner, Ph.D. | Management | Withheld | For | |||||
1J. | SARISSA NOMINEE: Sarah J. Schlesinger, M.D. | Management | Withheld | For | |||||
2. | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. | Management | For | For | |||||
3. | To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration. | Management | For | For | |||||
4. | To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Management | For | For | |||||
5. | To renew Board authority to allot and issue shares under Irish law. | Management | For | For | |||||
6. | To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law. | Management | For | For |
ALNYLAM PHARMACEUTICALS, INC.
Security | 02043Q107 | Meeting Type | Annual |
Ticker Symbol | ALNY | Meeting Date | 18-May-2023 |
Record Date | 24-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class I Director: Michael W. Bonney | Management | For | For | |||||
1b. | Election of Class I Director: Yvonne L. Greenstreet, MBChB, MBA | Management | For | For | |||||
1c. | Election of Class I Director: Phillip A. Sharp, Ph.D. | Management | For | For | |||||
1d. | Election of Class I Director: Elliott Sigal, M.D., Ph.D. | Management | For | For | |||||
2 | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. | Management | For | For | |||||
3. | To recommend, in a non-binding advisory vote, the frequency of advisory stockholder votes on executive compensation. | Management | 1 Year | For | |||||
4. | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2023. | Management | For | For |
AMEDISYS, INC.
Security | 023436108 | Meeting Type | Annual |
Ticker Symbol | AMED | Meeting Date | 08-Jun-2023 |
Record Date | 11-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Richard M. Ashworth | For | For | |||||||
2 | Vickie L. Capps | For | For | |||||||
3 | Molly J. Coye, MD | For | For | |||||||
4 | Julie D. Klapstein | For | For | |||||||
5 | Teresa L. Kline | For | For | |||||||
6 | Paul B. Kusserow | For | For | |||||||
7 | Bruce D. Perkins | For | For | |||||||
8 | Jeffery A. Rideout, MD | For | For | |||||||
9 | Ivanetta Davis Samuels | For | For | |||||||
2. | To ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | To approve, on an advisory (non-binding) basis, the compensation paid to the Company's Named Executive Officers, as set forth in the Company's 2023 Proxy Statement ("Say on Pay" Vote). | Management | For | For | ||||||
4. | To approve, on an advisory (non-binding) basis, the frequency of future stockholder Say on Pay Votes. | Management | 1 Year | For |
AMGEN INC.
Security | 031162100 | Meeting Type | Annual |
Ticker Symbol | AMGN | Meeting Date | 19-May-2023 |
Record Date | 20-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Wanda M. Austin | Management | For | For | |||||
1b. | Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Bradway | Management | For | For | |||||
1c. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Michael V. Drake | Management | For | For | |||||
1d. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Brian J. Druker | Management | For | For | |||||
1e. | Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Eckert | Management | For | For | |||||
1f. | Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Greg C. Garland | Management | For | For | |||||
1g. | Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Charles M. Holley, Jr. | Management | For | For | |||||
1h. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. S. Omar Ishrak | Management | For | For | |||||
1i. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Tyler Jacks | Management | For | For | |||||
1j. | Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Ellen J. Kullman | Management | For | For | |||||
1k. | Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Amy E. Miles | Management | For | For | |||||
1l. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Ronald D. Sugar | Management | For | For | |||||
1m. | Election of Director for a term of office expiring at the 2024 annual meeting: Dr. R. Sanders Williams | Management | For | For | |||||
2. | Advisory vote on the frequency of future stockholder advisory votes to approve executive compensation. | Management | 1 Year | For | |||||
3. | Advisory vote to approve our executive compensation. | Management | For | For | |||||
4. | To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2023. | Management | For | For |
AMOLYT PHARMA
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 21-Jun-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the company’s 2022 financials and earnings, discharge of the President for the performance of his duties during the past fiscal year | Management | For | For | |||||
2. | Approval of amendment No. 1 dated November 13, 2022 and the amendment No. 2 dated January 6, 2023 to the service agreement entered into on July 25, 2019 between the Company and Tab Consulting, of which Mr. Thierry Abribat is chairman, the terms of which are described in the special report of the Statutory Auditor | Management | For | For | |||||
3. | Approval of amendment No.2 dated April 7, 2022 and the amendment No. 3 dated March 8, 2023 to the consulting agreement entered into on May 6, 2020 between the Company and Stone Atlanta Estates LLC (formerly Stone Sunny Isles, Inc.), of which Mr. Pierre Legault is president, the terms of which are described in the special report of the Statutory Auditor | Management | For | For | |||||
4. | Approval of amendment No.1 dated January 6, 2023 to the indemnification agreement entered into on June 3, 2020 between the Company and Mr. Pierre Legault, the terms of which are described in the special report of the Statutory Auditor. | Management | For | For | |||||
5. | Reappointment of Pierre Legault as a member of the Board of Directors | Management | For | For | |||||
6. | Approval of the 2023-1 stock option plan adopted by the President on March 1, 2023 | Management | For | For |
AMPHIVENA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 26-Sep-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | General Assignment | Management | For | For | |||||
2. | Assignment Amendment | Management | For | For |
APELLIS PHARMACEUTICALS INC.
Security | 03753U106 | Meeting Type | Annual |
Ticker Symbol | APLS | Meeting Date | 01-Jun-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class III Director to hold office until the 2026 annual meeting: Gerald Chan | Management | For | For | |||||
1.2 | Election of Class III Director to hold office until the 2026 annual meeting: Cedric Francois | Management | For | For | |||||
2. | To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | To approve an advisory vote on executive compensation. | Management | For | For |
ARCUTIS BIOTHERAPEUTICS, INC.
Security | 03969K108 | Meeting Type | Annual |
Ticker Symbol | ARQT | Meeting Date | 31-May-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class III Director to hold office until the 2026 Annual Meeting: Patrick J. Heron | Management | For | For | |||||
1b. | Election of Class III Director to hold office until the 2026 Annual Meeting: Neha Krishnamohan | Management | For | For | |||||
1c. | Election of Class III Director to hold office until the 2026 Annual Meeting: Todd Franklin Watanabe | Management | For | For | |||||
2. | To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. | Management | For | For |
ARGENX SE
Security | 04016X101 | Meeting Type | Special |
Ticker Symbol | ARGX | Meeting Date | 08-Sep-2022 |
Record Date | 02-Aug-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
2. | Appointment of Camilla Sylvest as non-executive director to the board of directors of the Company | Management | For |
ARGENX SE
Security | 04016X101 | Meeting Type | Special |
Ticker Symbol | ARGX | Meeting Date | 12-Dec-2022 |
Record Date | 08-Nov-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
2. | Appointment of Ana Cespedes as non-executive director to the board of directors of the Company | Management | Abstain |
ARGENX SE
Security | 04016X101 | Meeting Type | Annual |
Ticker Symbol | ARGX | Meeting Date | 02-May-2023 |
Record Date | 04-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
3. | Advisory vote to approve the 2022 remuneration report. | Management | For | ||||||
4b. | Adoption of the 2022 annual accounts. | Management | For | ||||||
4d. | Allocation of losses of the Company in the financial year 2021 to the retained earnings of the Company. | Management | For | ||||||
4e. | Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2022. | Management | For | ||||||
5. | Proposal to re-appoint Don deBethizy as non-executive director for a term of two years. | Management | For | ||||||
6. | Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any. | Management | For | ||||||
7. | Appointment of Deloitte Accountants B.V. as statutory auditor for the 2023 financial year. | Management | For |
ARISTEA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 7-Jul-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Appoint Independent director | Management | For | For |
ARISTEA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 7-Jul-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Appoint Series A director | Management | For | For |
ARKUDA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 19-Dec-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Second Tranche Closing under Series B Preferred Stock Purchase Agreement | Management | For | For |
ARKUDA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 13-Apr-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment No. 1 to amended and restated voting agreement and stockholder consent | Management | For | For |
ARROWHEAD PHARMACEUTICALS, INC.
Security | 04280A100 | Meeting Type | Annual |
Ticker Symbol | ARWR | Meeting Date | 16-Mar-2023 |
Record Date | 20-Jan-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Douglass Given | Management | For | For | |||||
1b. | Election of Director: Michael S. Perry | Management | For | For | |||||
1c. | Election of Director: Christopher Anzalone | Management | For | For | |||||
1d. | Election of Director: Marianne De Backer | Management | For | For | |||||
1e. | Election of Director: Mauro Ferrari | Management | For | For | |||||
1f. | Election of Director: Adeoye Olukotun | Management | For | For | |||||
1g. | Election of Director: William Waddill | Management | For | For | |||||
1h. | Election of Director: Victoria Vakiener | Management | For | For | |||||
2. | Advisory Vote to Approve Executive Compensation. | Management | For | For | |||||
3. | Approval of Amendment to Arrowhead Pharmaceuticals, Inc.'s Amended and Restated Certificate Of Incorporation To Increase The Number Of Authorized Shares Of Common Stock. | Management | For | For | |||||
4. | To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2023. | Management | For | For |
ASCENDIS PHARMA A/S
Security | 04351P101 | Meeting Type | Special |
Ticker Symbol | ASND | Meeting Date | 09-Sep-2022 |
Record Date | 02-Aug-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting. | Management | For | For | |||||
2a. | Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: William Carl Fairey Jr | Management | For | For | |||||
2b. | Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: Siham Imani | Management | For | For | |||||
3. | The board of directors proposes to authorize the chairman of the meeting (with a right of substitution) on behalf of the Company to apply the Danish Business Authority for registration of the resolution passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company's articles of association and these minutes of the general meeting, that may be required as a condition for registration. | Management | For | For |
ASCENDIS PHARMA A/S
Security | 04351P101 | Meeting Type | Annual |
Ticker Symbol | ASND | Meeting Date | 30-May-2023 |
Record Date | 21-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting. | Management | For | For | |||||
2. | Chairman of the Board, Albert Cha, and Chief Executive Officer, Jan Møller Mikkelsen or Chief Legal Officer, Michael Wolff Jensen will report on the Company's activities for the year ended December 31, 2022. | Management | For | For | |||||
3. | The Board of Directors recommends that the audited annual report will be adopted and that a resolution will be passed to discharge the Board of Directors and Management from liability. | Management | For | For | |||||
4. | The Board of Directors proposes that the consolidated loss for the year of EUR 583.2 million be carried forward to next year through recognition in accumulated deficit. | Management | For | For | |||||
5a. | Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Jan Møller Mikkelsen | Management | For | For | |||||
5b. | Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Lisa Morrison | Management | For | For | |||||
5c. | Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: William Carl Fairey Jr | Management | For | For | |||||
5d. | Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Siham Imani | Management | For | For | |||||
6. | The Board of Directors proposes that Deloitte Statsautoriseret Revisionspartnerselskab be re-appointed as the Company's auditor. | Management | For | For | |||||
7. | Proposal from the Board of Directors The Board of Directors proposes that the following authorization is adopted: The Board of Directors is authorized, in accordance with the Danish Companies Act, Section 198, during the period until 29 May 2028 on one or more occasions to purchase up to nominal DKK 1,000,000 shares or American Depositary Shares representing a corresponding amount of shares in the Company as treasury shares. The minimum price per share shall be DKK 1 and the maximum price per share shall not exceed the market price. | Management | For | For |
ASTRAZENECA PLC
Security | 046353108 | Meeting Type | Annual |
Ticker Symbol | AZN | Meeting Date | 27-Apr-2023 |
Record Date | 10-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022 | Management | For | For | |||||
2. | To confirm dividends | Management | For | For | |||||
3. | To reappoint PricewaterhouseCoopers LLP as Auditor | Management | For | For | |||||
4. | To authorise the Directors to agree the remuneration of the Auditor | Management | For | For | |||||
5a. | Re-election of Director: Michel Demaré | Management | For | For | |||||
5b. | Re-election of Director: Pascal Soriot | Management | For | For | |||||
5c. | Re-election of Director: Aradhana Sarin | Management | For | For | |||||
5d. | Re-election of Director: Philip Broadley | Management | For | For | |||||
5e. | Re-election of Director: Euan Ashley | Management | For | For | |||||
5f. | Re-election of Director: Deborah DiSanzo | Management | For | For | |||||
5g. | Re-election of Director: Diana Layfield | Management | For | For | |||||
5h. | Re-election of Director: Sheri McCoy | Management | For | For | |||||
5i. | Re-election of Director: Tony Mok | Management | For | For | |||||
5j. | Re-election of Director: Nazneen Rahman | Management | For | For | |||||
5k. | Re-election of Director: Andreas Rummelt | Management | For | For | |||||
5l. | Re-election of Director: Marcus Wallenberg | Management | For | For | |||||
6. | To approve the Annual Report on Remuneration for the year ended 31 December 2022 | Management | For | For | |||||
7. | To authorise limited political donations | Management | For | For | |||||
8. | To authorise the Directors to allot shares | Management | For | For | |||||
9. | To authorise the Directors to disapply pre-emption rights (Special Resolution) | Management | For | For | |||||
10. | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution) | Management | For | For | |||||
11. | To authorise the Company to purchase its own shares (Special Resolution) | Management | For | For | |||||
12. | To reduce the notice period for general meetings (Special Resolution) | Management | For | For | |||||
13. | To adopt new Articles of Association (Special Resolution) | Management | For | For |
ASTRAZENECA PLC
Security | 046353108 | Meeting Type | Annual |
Ticker Symbol | AZN | Meeting Date | 27-Apr-2023 |
Record Date | 04-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022 | Management | For | For | |||||
2. | To confirm dividends | Management | For | For | |||||
3. | To reappoint PricewaterhouseCoopers LLP as Auditor | Management | For | For | |||||
4. | To authorise the Directors to agree the remuneration of the Auditor | Management | For | For | |||||
5a. | Re-election of Director: Michel Demaré | Management | For | For | |||||
5b. | Re-election of Director: Pascal Soriot | Management | For | For | |||||
5c. | Re-election of Director: Aradhana Sarin | Management | For | For | |||||
5d. | Re-election of Director: Philip Broadley | Management | For | For | |||||
5e. | Re-election of Director: Euan Ashley | Management | For | For | |||||
5f. | Re-election of Director: Deborah DiSanzo | Management | For | For | |||||
5g. | Re-election of Director: Diana Layfield | Management | For | For | |||||
5h. | Re-election of Director: Sheri McCoy | Management | For | For | |||||
5i. | Re-election of Director: Tony Mok | Management | For | For | |||||
5j. | Re-election of Director: Nazneen Rahman | Management | For | For | |||||
5k. | Re-election of Director: Andreas Rummelt | Management | For | For | |||||
5l. | Re-election of Director: Marcus Wallenberg | Management | For | For | |||||
6. | To approve the Annual Report on Remuneration for the year ended 31 December 2022 | Management | For | For | |||||
7. | To authorise limited political donations | Management | For | For | |||||
8. | To authorise the Directors to allot shares | Management | For | For | |||||
9. | To authorise the Directors to disapply pre-emption rights (Special Resolution) | Management | For | For | |||||
10. | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution) | Management | For | For | |||||
11. | To authorise the Company to purchase its own shares (Special Resolution) | Management | For | For | |||||
12. | To reduce the notice period for general meetings (Special Resolution) | Management | For | For | |||||
13. | To adopt new Articles of Association (Special Resolution) | Management | For | For |
BIOCRYST PHARMACEUTICALS, INC.
Security | 09058V103 | Meeting Type | Annual |
Ticker Symbol | BCRX | Meeting Date | 13-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | George B. Abercrombie | For | For | |||||||
2 | Theresa M. Heggie | For | For | |||||||
3 | Amy E. McKee, M.D. | For | For | |||||||
4 | Jon P. Stonehouse | For | For | |||||||
2. | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2023. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the Company's executive compensation. | Management | For | For | ||||||
4. | To provide an advisory vote on the frequency of future advisory votes on the Company's executive compensation. | Management | 1 Year | For | ||||||
5. | To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares. | Management | For | For |
BIOGEN INC.
Security | 09062X103 | Meeting Type | Annual |
Ticker Symbol | BIIB | Meeting Date | 26-Jun-2023 |
Record Date | 20-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable | Management | For | For | |||||
1b. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Caroline D. Dorsa | Management | For | For | |||||
1c. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Maria C. Freire | Management | For | For | |||||
1d. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: William A. Hawkins | Management | For | For | |||||
1e. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable | Management | For | For | |||||
1f. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Jesus B. Mantas | Management | For | For | |||||
1g. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable | Management | For | For | |||||
1h. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Eric K. Rowinsky | Management | For | For | |||||
1i. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Stephen A. Sherwin | Management | For | For | |||||
1j. | Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Christopher A. Viehbacher | Management | For | For | |||||
2. | To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | Say on Pay - To approve an advisory vote on executive compensation. | Management | For | For | |||||
4. | Say When on Pay - To approve an advisory vote on the frequency of the advisory vote on executive compensation. | Management | 1 Year | For | |||||
5. | To elect Susan Langer as a director | Management |
BIOHAVEN LTD
Security | G1110E107 | Meeting Type | Annual |
Ticker Symbol | BHVN | Meeting Date | 02-May-2023 |
Record Date | 06-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Michael T. Heffernan | Management | For | For | |||||
1b. | Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Irina A. Antonijevic, M.D., Ph.D. | Management | For | For | |||||
1c. | Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Robert J. Hugin | Management | For | For | |||||
2. | Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2023. | Management | For | For |
BIOHAVEN PHARMACEUTICAL HLDG CO LTD
Security | G11196105 | Meeting Type | Special |
Ticker Symbol | BHVN | Meeting Date | 29-Sep-2022 |
Record Date | 29-Aug-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To adopt (i) the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), Pfizer Inc. & Bulldog (BVI) Ltd., (ii) the form of Plan of Reverse Triangular Merger & form of Plan of Forward Triangular Merger (together, the "Plan of Merger") & (iii) Separation & Distribution Agreement, dated as of May 9, 2022 ("Distribution Agreement"), by and between Biohaven & Biohaven Research Ltd. ("SpinCo"), in each case, as they may be amended from time to time. | Management | For | For | |||||
2. | To approve, by non-binding, advisory vote, certain compensatory arrangements for Biohaven's named executive officers in connection with the acquisition by Pfizer of Biohaven and the distribution to Biohaven's shareholders of all of the issued and outstanding common shares of SpinCo. | Management | For | For | |||||
3. | To adjourn the Special Meeting, if necessary, desirable or appropriate, to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes to adopt the Merger Agreement, the Plan of Merger and the Distribution Agreement. | Management | For | For |
BIOMARIN PHARMACEUTICAL INC.
Security | 09061G101 | Meeting Type | Annual |
Ticker Symbol | BMRN | Meeting Date | 23-May-2023 |
Record Date | 27-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Mark J. Alles | For | For | |||||||
2 | Elizabeth M. Anderson | For | For | |||||||
3 | Jean-Jacques Bienaimé | For | For | |||||||
4 | Willard Dere | For | For | |||||||
5 | Elaine J. Heron | For | For | |||||||
6 | Maykin Ho | For | For | |||||||
7 | Robert J. Hombach | For | For | |||||||
8 | V. Bryan Lawlis | For | For | |||||||
9 | Richard A. Meier | For | For | |||||||
10 | David E.I. Pyott | For | For | |||||||
11 | Dennis J. Slamon | For | For | |||||||
2. | To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the frequency of the stockholders' approval, on an advisory basis, of the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. | Management | 1 Year | For | ||||||
4. | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. | Management | For | For | ||||||
5. | To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended. | Management | For | For |
BIONTECH SE
Security | 09075V102 | Meeting Type | Annual |
Ticker Symbol | BNTX | Meeting Date | 25-May-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
2 | Resolution on the appropriation of the balance sheet profit for the financial year 2021. | Management | For | For | |||||
3 | Resolution on the appropriation of the balance sheet profit for the financial year 2022. | Management | For | For | |||||
4 | Resolution on the approval of the actions of the Management Board. | Management | For | For | |||||
5 | Resolution on the approval of the actions of the Supervisory Board. | Management | For | For | |||||
6 | Resolution on the appointment of the auditor of the financial statements and the auditor of the consolidated financial statements for the financial year 2023 as well as the auditor for a possible audit or audit review of interim reports. | Management | For | For | |||||
7 | Resolution on the approval of the remuneration report. | Management | For | For | |||||
8.1 | Election to the Supervisory Board: Baroness Nicola Blackwood | Management | For | For | |||||
8.2 | Election to the Supervisory Board: Ulrich Wandschneider, Ph.D. | Management | For | For | |||||
8.3 | Election to the Supervisory Board: Mr. Michael Motschmann | Management | For | For | |||||
9 | Resolution on the Amendment to Sec. 16 para. 5 of the Articles of Association to authorise the Management Board to provide for the holding of a virtual Annual General Meeting. | Management | For | For | |||||
10 | Resolution on the Amendment to Sec. 16 para. 4 of the Articles of Association on the participation of members of the Supervisory Board in the Annual General Meeting by means of video and audio transmission. | Management | For | For | |||||
11a | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Idar-Oberstein Services GmbH as dependent company. | Management | For | For | |||||
11b | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and NT Security and Services GmbH as dependent company. | Management | For | For | |||||
11c | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech BioNTainer Holding GmbH as dependent company. | Management | For | For | |||||
11d | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Individualized mRNA Manufacturing GmbH as dependent company. | Management | For | For |
BLACK DIAMOND THERAPEUTICS, INC.
Security | 09203E105 | Meeting Type | Annual |
Ticker Symbol | BDTX | Meeting Date | 16-May-2023 |
Record Date | 20-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class III Director: David M. Epstein | Management | For | For | |||||
1b. | Election of Class III Director: Wendy L. Dixon | Management | For | For | |||||
1c. | Election of Class III Director: Kapil Dhingra | Management | For | For | |||||
2. | To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.'s independent registered accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
BLUEPRINT MEDICINES CORPORATION
Security | 09627Y109 | Meeting Type | Annual |
Ticker Symbol | BPMC | Meeting Date | 21-Jun-2023 |
Record Date | 24-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Alexis Borisy | For | For | |||||||
2 | Lonnel Coats | For | For | |||||||
3 | Kathryn Haviland | For | For | |||||||
2. | Approve a non-binding, advisory vote on the compensation paid to our named executive officers. | Management | For | For | ||||||
3. | Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
BOSTON SCIENTIFIC CORPORATION
Security | 101137107 | Meeting Type | Annual |
Ticker Symbol | BSX | Meeting Date | 04-May-2023 |
Record Date | 10-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Nelda J. Connors | Management | For | For | |||||
1b. | Election of Director: Charles J. Dockendorff | Management | For | For | |||||
1c. | Election of Director: Yoshiaki Fujimori | Management | For | For | |||||
1d. | Election of Director: Edward J. Ludwig | Management | For | For | |||||
1e. | Election of Director: Michael F. Mahoney | Management | For | For | |||||
1f. | Election of Director: David J. Roux | Management | For | For | |||||
1g. | Election of Director: John E. Sununu | Management | For | For | |||||
1h. | Election of Director: David S. Wichmann | Management | For | For | |||||
1i. | Election of Director: Ellen M. Zane | Management | For | For | |||||
2. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | |||||
3. | To approve, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of our named executive officers. | Management | 1 Year | For | |||||
4. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2023 fiscal year. | Management | For | For |
BRIDGEBIO PHARMA INC.
Security | 10806X102 | Meeting Type | Annual |
Ticker Symbol | BBIO | Meeting Date | 21-Jun-2023 |
Record Date | 24-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | James C. Momtazee | For | For | |||||||
2 | Frank McCormick, Ph.D. | For | For | |||||||
3 | Randal W. Scott, Ph.D. | For | For | |||||||
4 | Hannah A. Valantine MD | For | For | |||||||
2. | To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. | Management | For | For | ||||||
3. | To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. | Management | For | For |
BRISTOL-MYERS SQUIBB COMPANY
Security | 110122108 | Meeting Type | Annual |
Ticker Symbol | BMY | Meeting Date | 02-May-2023 |
Record Date | 13-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Peter J. Arduini | Management | For | For | |||||
1B. | Election of Director: Deepak L. Bhatt, M.D., M.P.H. | Management | For | For | |||||
1C. | Election of Director: Giovanni Caforio, M.D. | Management | For | For | |||||
1D. | Election of Director: Julia A. Haller, M.D. | Management | For | For | |||||
1E. | Election of Director: Manuel Hidalgo Medina, M.D., Ph.D. | Management | For | For | |||||
1F. | Election of Director: Paula A. Price | Management | For | For | |||||
1G. | Election of Director: Derica W. Rice | Management | For | For | |||||
1H. | Election of Director: Theodore R. Samuels | Management | For | For | |||||
1I. | Election of Director: Gerald L. Storch | Management | For | For | |||||
1J. | Election of Director: Karen H. Vousden, Ph.D. | Management | For | For | |||||
1K. | Election of Director: Phyllis R. Yale | Management | For | For | |||||
2. | Advisory Vote to Approve the Compensation of our Named Executive Officers. | Management | For | For | |||||
3. | Advisory Vote on the Frequency of the Advisory Vote on the Compensation of our Named Executive Officers. | Management | 1 Year | For | |||||
4. | Ratification of the Appointment of an Independent Registered Public Accounting Firm. | Management | For | For | |||||
5. | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director. | Shareholder | For | Against | |||||
6. | Shareholder Proposal on Workplace Non-Discrimination Audit. | Shareholder | Against | For | |||||
7. | Shareholder Proposal on Special Shareholder Meeting Improvement. | Shareholder | Against | For |
CARDIOVASCULAR SYSTEMS, INC.
Security | 141619106 | Meeting Type | Special |
Ticker Symbol | CSII | Meeting Date | 27-Apr-2023 |
Record Date | 14-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To adopt the Agreement and Plan of Merger, dated February 8, 2023 (such agreement, as it may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among Cardiovascular Systems, Inc. ("CSI"), Abbott Laboratories ("Abbott"), and Cobra Acquisition Co. ("Merger Sub"). Upon the terms and subject to the conditions of the Merger Agreement, Abbott will acquire CSI via a merger of Merger Sub with and into CSI, with CSI continuing as the surviving corporation and a wholly owned subsidiary of Abbott (the "Merger"). | Management | For | For | |||||
2. | To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to CSI's named executive officers that is based on or otherwise relates to the Merger Agreement, the Merger, and the other transactions contemplated by the Merger Agreement. | Management | For | For | |||||
3. | To adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the proposal to adopt the Merger Agreement if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting. | Management | For | For |
CARIBOU BIOSCIENCES, INC.
Security | 142038108 | Meeting Type | Annual |
Ticker Symbol | CRBU | Meeting Date | 20-Sep-2022 |
Record Date | 04-Aug-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class 1 Director: Scott Braunstein, M.D. | Management | For | For | |||||
1b. | Election of Class 1 Director: Ran Zheng, M.S. | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022 | Management | For | For |
CARIBOU BIOSCIENCES, INC.
Security | 142038108 | Meeting Type | Annual |
Ticker Symbol | CRBU | Meeting Date | 15-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class II Director: Andrew Guggenhime, M.B.A. | Management | For | For | |||||
1b. | Election of Class II Director: David L. Johnson, M.B.A. | Management | For | For | |||||
1c. | Election of Class II Director: Nancy Whiting, Pharm.D. | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 | Management | For | For |
CEREVEL THERAPEUTICS HOLDINGS, INC.
Security | 15678U128 | Meeting Type | Annual |
Ticker Symbol | CERE | Meeting Date | 07-Jun-2023 |
Record Date | 10-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Marijn Dekkers | Management | For | For | |||||
1.2 | Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Deval Patrick | Management | For | For | |||||
1.3 | Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Norbert Riedel | Management | For | For | |||||
1.4 | Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Gabrielle Sulzberger | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023. | Management | For | For |
CHARLES RIVER LABORATORIES INTL., INC.
Security | 159864107 | Meeting Type | Annual |
Ticker Symbol | CRL | Meeting Date | 09-May-2023 |
Record Date | 16-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: James C. Foster | Management | For | For | |||||
1b. | Election of Director: Nancy C. Andrews | Management | For | For | |||||
1c. | Election of Director: Robert Bertolini | Management | For | For | |||||
1d. | Election of Director: Deborah T. Kochevar | Management | For | For | |||||
1e. | Election of Director: George Llado, Sr. | Management | For | For | |||||
1f. | Election of Director: Martin W. Mackay | Management | For | For | |||||
1g. | Election of Director: George E. Massaro | Management | For | For | |||||
1h. | Election of Director: C. Richard Reese | Management | For | For | |||||
1i. | Election of Director: Craig B. Thompson | Management | For | For | |||||
1j. | Election of Director: Richard F. Wallman | Management | For | For | |||||
1k. | Election of Director: Virginia M. Wilson | Management | For | For | |||||
2. | Advisory Approval of 2022 Executive Officer Compensation | Management | For | For | |||||
3. | Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation | Management | 1 Year | For | |||||
4. | Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2023 | Management | For | For | |||||
5. | Proposal to publish a report on non-human primates imported by Charles River Laboratories International, Inc. | Management | Against | For |
CHEMOCENTRYX, INC.
Security | 16383L106 | Meeting Type | Special |
Ticker Symbol | CCXI | Meeting Date | 18-Oct-2022 |
Record Date | 13-Sep-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To adopt the Agreement and Plan of Merger, dated as of August 3, 2022 (the "Merger Agreement"), by and among ChemoCentryx, Inc. ("ChemoCentryx"), Amgen Inc. ("Amgen") and Carnation Merger Sub, Inc., a wholly owned subsidiary of Amgen ("Merger Sub"), pursuant to which Merger Sub will be merged with and into ChemoCentryx (the "Merger") with ChemoCentryx surviving the Merger as a wholly owned subsidiary of Amgen. | Management | For | For | |||||
2. | To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to ChemoCentryx's named executive officers that is based on or otherwise relates to the Merger. | Management | For | For | |||||
3. | To approve the adjournment of the Special Meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting. | Management | For | For |
CHINOOK THERAPEUTICS, INC.
Security | 16961L106 | Meeting Type | Annual |
Ticker Symbol | KDNY | Meeting Date | 09-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Michelle Griffin | For | For | |||||||
2 | Eric Dobmeier | For | For | |||||||
2. | Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | Advisory vote on the compensation of the Company's named executive officers. | Management | For | For | ||||||
4. | Approval of the Company's Amended and Restated Certificate of Incorporation. | Management | For | For | ||||||
5. | Approval of the Company's Amended and Restated 2015 Equity Incentive Plan. | Management | For | For |
CURASEN THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 21-Oct-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment To Certificate Of Incorporation | Management | For | For | |||||
2. | Series A Preferred Stock Extension Financing | Management | For | For | |||||
3. | Waiver of Preemptive Rights | Management | For | For | |||||
4. | General Authority and Ratification | Management | For | For |
CURASEN THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 3-Jan-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment to Amended and Restated 2016 Equity Incentive Plan | Management | For | For | |||||
2. | General Authority and Ratification | Management | For | For |
CYTOKINETICS, INCORPORATED
Security | 23282W605 | Meeting Type | Annual |
Ticker Symbol | CYTK | Meeting Date | 10-May-2023 |
Record Date | 21-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class I Director: Edward M. Kaye, M.D. | Management | For | For | |||||
1b. | Election of Class I Director: Wendell Wierenga, Ph.D. | Management | For | For | |||||
1c. | Election of Class I Director: Nancy J. Wysenski | Management | For | For | |||||
2. | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of the Company's directors. | Management | For | For | |||||
3. | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of senior officers of the Company. | Management | For | For | |||||
4. | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
5. | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. | Management | For | For | |||||
6. | To determine, on an advisory basis, the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the named executive officers. | Management | 1 Year | For |
DANAHER CORPORATION
Security | 235851102 | Meeting Type | Annual |
Ticker Symbol | DHR | Meeting Date | 09-May-2023 |
Record Date | 10-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Rainer M. Blair | Management | For | For | |||||
1b. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Feroz Dewan | Management | For | For | |||||
1c. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Linda Filler | Management | For | For | |||||
1d. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Teri List | Management | For | For | |||||
1e. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Walter G. Lohr, Jr. | Management | For | For | |||||
1f. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Jessica L. Mega, MD, MPH | Management | For | For | |||||
1g. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Mitchell P. Rales | Management | For | For | |||||
1h. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Steven M. Rales | Management | For | For | |||||
1i. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Pardis C. Sabeti, MD, D. PHIL | Management | For | For | |||||
1j. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: A. Shane Sanders | Management | For | For | |||||
1k. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: John T. Schwieters | Management | For | For | |||||
1l. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Alan G. Spoon | Management | For | For | |||||
1m. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Raymond C. Stevens, Ph.D | Management | For | For | |||||
1n. | Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Elias A. Zerhouni, MD | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
3. | To approve on an advisory basis the Company's named executive officer compensation. | Management | For | For | |||||
4. | To hold an advisory vote relating to the frequency of future shareholder advisory votes on the Company's executive officer compensation. | Management | 1 Year | For | |||||
5. | To act upon a shareholder proposal requesting adoption of a policy separating the chair and CEO roles and requiring an independent Board Chair whenever possible. | Shareholder | For | Against | |||||
6. | To act upon a shareholder proposal requesting a report to shareholders on the effectiveness of the Company's diversity, equity and inclusion efforts. | Shareholder | Against | For |
DENALI THERAPEUTICS INC.
Security | 24823R105 | Meeting Type | Annual |
Ticker Symbol | DNLI | Meeting Date | 01-Jun-2023 |
Record Date | 04-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Jennifer Cook | For | For | |||||||
2 | David Schenkein, M.D. | For | For | |||||||
3 | Ryan Watts, Ph.D. | For | For | |||||||
2. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023 | Management | For | For | ||||||
3. | Advisory vote on executive compensation | Management | For | For |
DEXCOM, INC.
Security | 252131107 | Meeting Type | Annual |
Ticker Symbol | DXCM | Meeting Date | 18-May-2023 |
Record Date | 29-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director to hold office until our 2024 Annual Meeting: Steven R. Altman | Management | For | For | |||||
1.2 | Election of Director to hold office until our 2024 Annual Meeting: Richard A. Collins | Management | For | For | |||||
1.3 | Election of Director to hold office until our 2024 Annual Meeting: Karen Dahut | Management | For | For | |||||
1.4 | Election of Director to hold office until our 2024 Annual Meeting: Mark G. Foletta | Management | For | For | |||||
1.5 | Election of Director to hold office until our 2024 Annual Meeting: Barbara E. Kahn | Management | For | For | |||||
1.6 | Election of Director to hold office until our 2024 Annual Meeting: Kyle Malady | Management | For | For | |||||
1.7 | Election of Director to hold office until our 2024 Annual Meeting: Eric J. Topol, M.D. | Management | For | For | |||||
2. | To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | To hold a non-binding vote on an advisory resolution to approve executive compensation. | Management | For | For | |||||
4. | To recommend a non-binding advisory resolution on the frequency of stockholder votes on executive compensation. | Management | 1 Year | For | |||||
5. | To hold a non-binding vote on pay equity disclosure. | Management | Against | For |
DYNACURE
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 10-Oct-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To approve the Term Sheet and the principle of the Merger subject to the terms and conditions set forth therein; and | Management | For | For | |||||
2. | To waive their rights to the liquidation preference under the Shareholders’ Agreement in connection with the contemplated Merger, subject to their replacement by new preference rights as described in the Term Sheet | Management | For | For |
DYNACURE
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 23-Jan-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Merger with Flamingo | Management | For | For |
EDWARDS LIFESCIENCES CORPORATION
Security | 28176E108 | Meeting Type | Annual |
Ticker Symbol | EW | Meeting Date | 11-May-2023 |
Record Date | 13-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Kieran T. Gallahue | Management | For | For | |||||
1.2 | Election of Director: Leslie S. Heisz | Management | For | For | |||||
1.3 | Election of Director: Paul A. LaViolette | Management | For | For | |||||
1.4 | Election of Director: Steven R. Loranger | Management | For | For | |||||
1.5 | Election of Director: Martha H. Marsh | Management | For | For | |||||
1.6 | Election of Director: Michael A. Mussallem | Management | For | For | |||||
1.7 | Election of Director: Ramona Sequeira | Management | For | For | |||||
1.8 | Election of Director: Nicholas J. Valeriani | Management | For | For | |||||
1.9 | Election of Director: Bernard J. Zovighian | Management | For | For | |||||
2. | Advisory Vote to Approve Named Executive Officer Compensation | Management | For | For | |||||
3. | Advisory Vote to Approve Frequency of Future Advisory Votes on Named Executive Officer Compensation | Management | 1 Year | For | |||||
4. | Ratification of Appointment of Independent Registered Public Accounting Firm | Management | For | For | |||||
5. | Approval of Amendment of the Certificate of Incorporation to Provide for Exculpation of Officers | Management | For | For | |||||
6. | Stockholder Proposal regarding Independent Board Chairman Policy | Shareholder | Against | For |
ELEVANCE HEALTH, INC.
Security | 036752103 | Meeting Type | Annual |
Ticker Symbol | ELV | Meeting Date | 10-May-2023 |
Record Date | 17-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Gail K. Boudreaux | Management | For | For | |||||
1b. | Election of Director: R. Kerry Clark | Management | For | For | |||||
1c. | Election of Director: Robert L. Dixon, Jr. | Management | For | For | |||||
1d. | Election of Director: Deanna D. Strable | Management | For | For | |||||
2. | Advisory vote to approve the compensation of our named executive officers. | Management | For | For | |||||
3. | Advisory vote on the frequency of the advisory vote to approve the compensation of our named executive officers. | Management | 1 Year | For | |||||
4. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2023. | Management | For | For | |||||
5. | Shareholder proposal to allow shareholders owning 10% or more of our common stock to call a special meeting of shareholders. | Shareholder | Against | For | |||||
6. | Shareholder proposal requesting annual reporting from third parties seeking financial support. | Shareholder | Against | For |
ELI LILLY AND COMPANY
Security | 532457108 | Meeting Type | Annual |
Ticker Symbol | LLY | Meeting Date | 01-May-2023 |
Record Date | 21-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to serve a three-year term: William G. Kaelin, Jr. | Management | For | For | |||||
1b. | Election of Director to serve a three-year term: David A. Ricks | Management | For | For | |||||
1c. | Election of Director to serve a three-year term: Marschall S. Runge | Management | For | For | |||||
1d. | Election of Director to serve a three-year term: Karen Walker | Management | For | For | |||||
2. | Approval, on an advisory basis, of the compensation paid to the company's named executive officers. | Management | For | For | |||||
3. | Advisory vote on frequency of future advisory votes on named executive officer compensation. | Management | 1 Year | For | |||||
4. | Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2023. | Management | For | For | |||||
5. | Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure. | Management | For | For | |||||
6. | Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions. | Management | For | For | |||||
7. | Shareholder proposal to publish an annual report disclosing lobbying activities. | Shareholder | Against | For | |||||
8. | Shareholder proposal to eliminate supermajority voting requirements. | Shareholder | Against | For | |||||
9. | Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. | Shareholder | Against | For | |||||
10. | Shareholder proposal to report on risks of supporting abortion. | Shareholder | Against | For | |||||
11. | Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements. | Shareholder | Against | For | |||||
12. | Shareholder proposal to report on effectiveness of the company's diversity, equity, and inclusion efforts. | Shareholder | Against | For | |||||
13. | Shareholder proposal to adopt a policy to require certain third-party organizations to annually report expenditures for political activities before Lilly contributes to an organization. | Shareholder | Against | For |
EXELIXIS, INC.
Security | 30161Q104 | Meeting Type | Contested-Annual |
Ticker Symbol | EXEL | Meeting Date | 31-May-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Company Nominee: Maria C. Freire | Management | For | For | |||||
1B. | Company Nominee: Alan M. Garber | Management | For | For | |||||
1C. | Company Nominee: Michael M. Morrissey | Management | For | For | |||||
1D. | Company Nominee: Stelios Papadopoulos | Management | For | For | |||||
1E. | Company Nominee: George Poste | Management | For | For | |||||
1F. | Company Nominee: Julie Anne Smith | Management | For | For | |||||
1G. | Company Nominee: Lance Willsey | Management | For | For | |||||
1H. | Company Nominee: Jacqueline Wright | Management | For | For | |||||
1I. | Company Nominee: Jack L. Wyszomierski | Management | For | For | |||||
1J. | Company Recommended Farallon-Caligan Nominee: Tomas J. Heyman | Management | For | For | |||||
1K. | Company Recommended Farallon-Caligan Nominee: Robert "Bob" Oliver, Jr. | Management | For | For | |||||
1L. | Farallon-Caligan Nominee: David E. Johnson | Management | Withheld | * | |||||
2. | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending December 29, 2023. | Management | For | For | |||||
3. | To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the Proxy Statement. | Management | For | For | |||||
4. | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Exelixis' named executive officers. | Management | 1 Year | For |
FLAMINGO THERAPEUTICS, INC
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 28-Mar-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Reports | Management | For | For | |||||
2. | Creation of new classes of shares according to the report of the board of directors in accordance with Articles 7:155, 7:179, 7:180 and 7:191 of the Companies and Associations Code | Management | For | For | |||||
3. | Issue of new shares by capital increase in cash | Management | For | For | |||||
4. | Cancellation and issuance of subscription rights | Management | For | For | |||||
5. | Issue of anti-dilutive subscription rights | Management | For | For | |||||
6. | Confirmation of the cancellation of all securities or rights giving access to the capital of Dynacure SA in the context of the merger | Management | For | For | |||||
7. | Proxies | Management | For | For |
FLAMINGO THERAPEUTICS, INC
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 19-May-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Acknowledgment of the report of the statutory auditor | Management | For | For | |||||
2. | Approval of the annual accounts for the fiscal year ended on 31 December 2022 | Management | For | For | |||||
3. | Allocation of the results | Management | For | For | |||||
4. | Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year | Management | For | For |
FUSION PHARMACEUTICALS INC
Security | 36118A100 | Meeting Type | Annual |
Ticker Symbol | FUSN | Meeting Date | 14-Jun-2023 |
Record Date | 18-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director to serve until the next annual meeting: Donald Bergstrom, M.D., Ph.D. | Management | For | For | |||||
1.2 | Election of Director to serve until the next annual meeting: Pablo Cagnoni, M.D. | Management | For | For | |||||
1.3 | Election of Director to serve until the next annual meeting: Johan Christenson, M.D., Ph.D. | Management | For | For | |||||
1.4 | Election of Director to serve until the next annual meeting: Barbara Duncan | Management | For | For | |||||
1.5 | Election of Director to serve until the next annual meeting: Steve Gannon | Management | For | For | |||||
1.6 | Election of Director to serve until the next annual meeting: Chau Khuong | Management | For | For | |||||
1.7 | Election of Director to serve until the next annual meeting: Philina Lee, Ph.D. | Management | For | For | |||||
1.8 | Election of Director to serve until the next annual meeting: Heather Preston, M.D. | Management | For | For | |||||
1.9 | Election of Director to serve until the next annual meeting: John Valliant, Ph.D. | Management | For | For | |||||
2. | To appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
G1 THERAPEUTICS, INC.
Security | 3621LQ109 | Meeting Type | Annual |
Ticker Symbol | GTHX | Meeting Date | 15-Jun-2023 |
Record Date | 18-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class III Director: Garry A. Nicholson | Management | For | For | |||||
1.2 | Election of Class III Director: Mark A. Velleca, M.D., Ph.D. | Management | For | For | |||||
1.3 | Election of Class III Director: Glenn P. Muir | Management | For | For | |||||
2. | An advisory (non-binding) vote to approve executive compensation | Management | For | For | |||||
3. | The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023 | Management | For | For |
GALERA THERAPEUTICS, INC.
Security | 36338D108 | Meeting Type | Annual |
Ticker Symbol | GRTX | Meeting Date | 14-Jun-2023 |
Record Date | 21-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Michael Powell, Ph.D. | For | For | |||||||
2 | Linda West | For | For | |||||||
2. | To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
GILEAD SCIENCES, INC.
Security | 375558103 | Meeting Type | Annual |
Ticker Symbol | GILD | Meeting Date | 03-May-2023 |
Record Date | 15-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Jacqueline K. Barton, Ph.D. | Management | For | For | |||||
1b. | Election of Director: Jeffrey A. Bluestone, Ph.D. | Management | For | For | |||||
1c. | Election of Director: Sandra J. Horning, M.D. | Management | For | For | |||||
1d. | Election of Director: Kelly A. Kramer | Management | For | For | |||||
1e. | Election of Director: Kevin E. Lofton | Management | For | For | |||||
1f. | Election of Director: Harish Manwani | Management | For | For | |||||
1g. | Election of Director: Daniel P. O'Day | Management | For | For | |||||
1h. | Election of Director: Javier J. Rodriguez | Management | For | For | |||||
1i. | Election of Director: Anthony Welters | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | Management | For | For | |||||
4. | To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation. | Management | 1 Year | For | |||||
5. | To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. | Management | For | For | |||||
6. | To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected. | Shareholder | Against | For | |||||
7. | To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting. | Shareholder | Against | For | |||||
8. | To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. | Shareholder | Against | For |
GUARDANT HEALTH, INC.
Security | 40131M109 | Meeting Type | Annual |
Ticker Symbol | GH | Meeting Date | 14-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class II Director: Ian Clark | Management | For | For | |||||
1b. | Election of Class II Director: Meghan Joyce | Management | For | For | |||||
1c. | Election of Class II Director: Samir Kaul | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
3. | Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. | Management | For | For |
HCA HEALTHCARE, INC.
Security | 40412C101 | Meeting Type | Annual |
Ticker Symbol | HCA | Meeting Date | 19-Apr-2023 |
Record Date | 24-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Thomas F. Frist III | Management | For | For | |||||
1b. | Election of Director: Samuel N. Hazen | Management | For | For | |||||
1c. | Election of Director: Meg G. Crofton | Management | For | For | |||||
1d. | Election of Director: Robert J. Dennis | Management | For | For | |||||
1e. | Election of Director: Nancy-Ann DeParle | Management | For | For | |||||
1f. | Election of Director: William R. Frist | Management | For | For | |||||
1g. | Election of Director: Hugh F. Johnston | Management | For | For | |||||
1h. | Election of Director: Michael W. Michelson | Management | For | For | |||||
1i. | Election of Director: Wayne J. Riley, M.D. | Management | For | For | |||||
1j. | Election of Director: Andrea B. Smith | Management | For | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
3. | To approve the HCA Healthcare, Inc. 2023 Employee Stock Purchase Plan. | Management | For | For | |||||
4. | Advisory vote to approve named executive officer compensation. | Management | For | For | |||||
5. | Stockholder proposal, if properly presented at the meeting, regarding political spending disclosure. | Shareholder | Against | For | |||||
6. | Stockholder proposal, if properly presented at the meeting, regarding amendment to Patient Safety and Quality of Care Committee charter. | Shareholder | Against | For |
HORIZON THERAPEUTICS PLC
Security | G46188101 | Meeting Type | Special |
Ticker Symbol | HZNP | Meeting Date | 24-Feb-2023 |
Record Date | 19-Jan-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Ordinary Resolution to approve the Scheme of Arrangement and authorize the directors of Horizon to take all such actions as they consider necessary or appropriate for carrying the Scheme of Arrangement into effect. | Management | For | For | |||||
2. | Special Resolution to amend the articles of association of Horizon so that any Horizon Shares that are issued on or after the Voting Record Time to persons other than Acquirer Sub or its nominee(s) will either be subject to the terms of the Scheme of Arrangement or be immediately and automatically acquired by Acquirer Sub and/or its nominee(s) for the Scheme Consideration. | Management | For | For | |||||
3. | Ordinary Resolution to approve, on a non-binding, advisory basis, specified compensatory arrangements between Horizon and its named executive officers relating to the Transaction. | Management | For | For | |||||
4. | Ordinary Resolution to approve any motion by the Chairman to adjourn the EGM or any adjournments thereof, to solicit additional proxies in favor of the approval of the resolutions if there are insufficient votes at the time of the EGM to approve resolutions 1 and 2. | Management | For | For |
HORIZON THERAPEUTICS PLC
Security | G46188111 | Meeting Type | Special |
Ticker Symbol | HZNP | Meeting Date | 24-Feb-2023 |
Record Date | 19-Jan-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | That the Scheme of Arrangement in its original form or with or subject to any modification(s), addition(s) or condition(s) approved or imposed by the Irish High Court be agreed to. | Management | For | For |
HUMANA INC.
Security | 444859102 | Meeting Type | Annual |
Ticker Symbol | HUM | Meeting Date | 20-Apr-2023 |
Record Date | 28-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a) | Election of Director: Raquel C. Bono, M.D. | Management | For | For | |||||
1b) | Election of Director: Bruce D. Broussard | Management | For | For | |||||
1c) | Election of Director: Frank A. D'Amelio | Management | For | For | |||||
1d) | Election of Director: David T. Feinberg, M.D. | Management | For | For | |||||
1e) | Election of Director: Wayne A. I. Frederick, M.D. | Management | For | For | |||||
1f) | Election of Director: John W. Garratt | Management | For | For | |||||
1g) | Election of Director: Kurt J. Hilzinger | Management | For | For | |||||
1h) | Election of Director: Karen W. Katz | Management | For | For | |||||
1i) | Election of Director: Marcy S. Klevorn | Management | For | For | |||||
1j) | Election of Director: William J. McDonald | Management | For | For | |||||
1k) | Election of Director: Jorge S. Mesquita | Management | For | For | |||||
1l) | Election of Director: Brad D. Smith | Management | For | For | |||||
2. | The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. | Management | For | For | |||||
3. | Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2023 proxy statement. | Management | For | For | |||||
4. | Non-binding advisory vote for the approval of the frequency with which future stockholder votes on the compensation of the named executive officers will be held. | Management | 1 Year | For |
ICON PLC
Security | G4705A100 | Meeting Type | Annual |
Ticker Symbol | ICLR | Meeting Date | 26-Jul-2022 |
Record Date | 06-Jun-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Dr. Steve Cutler | Management | For | For | |||||
1.2 | Election of Director: Dr. John Climax | Management | For | For | |||||
1.3 | Election of Director: Mr. Ronan Murphy | Management | For | For | |||||
2. | To review the Company's affairs and consider the Accounts and Reports | Management | For | For | |||||
3. | To authorise the fixing of the Auditors' Remuneration | Management | For | For | |||||
4. | To authorise the Company to allot shares | Management | For | For | |||||
5. | To disapply the statutory pre-emption rights | Management | For | For | |||||
6. | To disapply the statutory pre-emption rights for funding capital investment or acquisitions | Management | For | For | |||||
7. | To authorise the Company to make market purchases of shares | Management | For | For | |||||
8. | To authorise the price range at which the Company can reissue shares that it holds as treasury shares | Management | For | For |
IDEXX LABORATORIES, INC.
Security | 45168D104 | Meeting Type | Annual |
Ticker Symbol | IDXX | Meeting Date | 17-May-2023 |
Record Date | 20-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director (Proposal One): Daniel M. Junius | Management | For | For | |||||
1b. | Election of Director (Proposal One): Lawrence D. Kingsley | Management | For | For | |||||
1c. | Election of Director (Proposal One): Sophie V. Vandebroek, PhD | Management | For | For | |||||
2. | Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two). | Management | For | For | |||||
3. | Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three). | Management | For | For | |||||
4. | Advisory Vote on the Frequency of Advisory Votes on Executive Compensation. To recommend, by nonbinding advisory vote, the frequency of future advisory votes on the Company's executive compensation (Proposal Four). | Management | 1 Year | For |
ILLUMINA, INC.
Security | 452327109 | Meeting Type | Contested-Annual |
Ticker Symbol | ILMN | Meeting Date | 25-May-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Illumina Nominee: Frances Arnold, Ph.D. | Management | For | For | |||||
1B. | Illumina Nominee: Francis A. deSouza | Management | Withheld | For | |||||
1C. | Illumina Nominee: Caroline D. Dorsa | Management | Withheld | For | |||||
1D. | Illumina Nominee: Robert S. Epstein, M.D. | Management | Withheld | For | |||||
1E. | Illumina Nominee: Scott Gottlieb, M.D. | Management | For | For | |||||
1F. | Illumina Nominee: Gary S. Guthart, Ph.D. | Management | Withheld | For | |||||
1G. | Illumina Nominee: Philip W. Schiller | Management | For | For | |||||
1H. | Illumina Nominee: Susan E. Siegel | Management | For | For | |||||
1I. | Illumina Nominee: John W. Thompson | Management | Withheld | For | |||||
1J. | Icahn Group Nominee OPPOSED by the Company: Vincent J. Intrieri | Management | For | For | |||||
1K. | Icahn Group Nominee OPPOSED by the Company: Jesse A. Lynn | Management | Withheld | For | |||||
1L. | Icahn Group Nominee OPPOSED by the Company: Andrew J. Teno | Management | Withheld | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | �� | For | For | ||||
3. | To approve, on an advisory basis, the compensation provided to our named executive officers as disclosed in the Proxy Statement. | Management | Against | Against | |||||
4. | To approve, on an advisory basis, the frequency of holding an advisory vote to approve compensation provided to our "named executive officers". | Management | 1 Year | For | |||||
5. | To approve certain amendments to the Illumina, Inc. 2015 Stock and Incentive Plan | Management | For | For |
INTELLIA THERAPEUTICS, INC.
Security | 45826J105 | Meeting Type | Annual |
Ticker Symbol | NTLA | Meeting Date | 14-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Muna Bhanji, R.Ph. | For | For | |||||||
2 | John F. Crowley | For | For | |||||||
3 | Jesse Goodman, MD, MPH | For | For | |||||||
2. | Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | Approve, on a non-binding advisory basis, the compensation of the named executive officers. | Management | For | For | ||||||
4. | Approval of an amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorizeds shares of common stock from 120,000,000 to 240,000,000. | Management | For | For |
INTERCEPT PHARMACEUTICALS, INC.
Security | 45845P108 | Meeting Type | Annual |
Ticker Symbol | ICPT | Meeting Date | 24-May-2023 |
Record Date | 31-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to serve until the 2024 Annual Meeting: Paolo Fundarò | Management | For | For | |||||
1b. | Election of Director to serve until the 2024 Annual Meeting: Jerome Durso | Management | For | For | |||||
1c. | Election of Director to serve until the 2024 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D. | Management | For | For | |||||
1d. | Election of Director to serve until the 2024 Annual Meeting: Luca Benatti, Ph.D. | Management | For | For | |||||
1e. | Election of Director to serve until the 2024 Annual Meeting: Daniel Bradbury | Management | For | For | |||||
1f. | Election of Director to serve until the 2024 Annual Meeting: Keith Gottesdiener, M.D. | Management | For | For | |||||
1g. | Election of Director to serve until the 2024 Annual Meeting: Nancy Miller-Rich | Management | For | For | |||||
1h. | Election of Director to serve until the 2024 Annual Meeting: Mark Pruzanski, M.D. | Management | For | For | |||||
1i. | Election of Director to serve until the 2024 Annual Meeting: Dagmar Rosa-Bjorkeson | Management | For | For | |||||
1j. | Election of Director to serve until the 2024 Annual Meeting: Gino Santini | Management | For | For | |||||
1k. | Election of Director to serve until the 2024 Annual Meeting: Glenn Sblendorio | Management | For | For | |||||
2. | FOR the approval of the Company's 2023 Equity Incentive Plan. | Management | For | For | |||||
3. | FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. | Management | For | For | |||||
4. | FOR the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For |
INTRA-CELLULAR THERAPIES, INC.
Security | 46116X101 | Meeting Type | Annual |
Ticker Symbol | ITCI | Meeting Date | 23-Jun-2023 |
Record Date | 27-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Eduardo Rene Salas | Management | For | For | |||||
2. | To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
3. | To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. | Management | For | For |
INTUITIVE SURGICAL, INC.
Security | 46120E602 | Meeting Type | Annual |
Ticker Symbol | ISRG | Meeting Date | 27-Apr-2023 |
Record Date | 28-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Craig H. Barratt, Ph.D. | Management | For | For | |||||
1b. | Election of Director: Joseph C. Beery | Management | For | For | |||||
1c. | Election of Director: Gary S. Guthart, Ph.D. | Management | For | For | |||||
1d. | Election of Director: Amal M. Johnson | Management | For | For | |||||
1e. | Election of Director: Don R. Kania, Ph.D. | Management | For | For | |||||
1f. | Election of Director: Amy L. Ladd, M.D. | Management | For | For | |||||
1g. | Election of Director: Keith R. Leonard, Jr. | Management | For | For | |||||
1h. | Election of Director: Alan J. Levy, Ph.D. | Management | For | For | |||||
1i. | Election of Director: Jami Dover Nachtsheim | Management | For | For | |||||
1j. | Election of Director: Monica P. Reed, M.D. | Management | For | For | |||||
1k. | Election of Director: Mark J. Rubash | Management | For | For | |||||
2. | To approve, by advisory vote, the compensation of the Company's Named Executive Officers | Management | For | For | |||||
3. | To approve, by advisory vote, the frequency of the advisory vote on the compensation of the Company's Named Executive Officers. | Management | 1 Year | For | |||||
4. | The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
5. | The stockholder proposal regarding pay equity disclosure. | Shareholder | Against | For |
IO LIGHT HOLDINGS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 27-Sep-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of Subsidiary Transfer Documents | Management | For | For | |||||
2. | General Resolutions | Management | For | For |
IO LIGHT HOLDINGS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 30-Dec-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of Series B Financing | Management | For | For | |||||
2. | Approval of Amended and Restated Certification of Incorporation | Management | For | For | |||||
3. | Approval of Amended and Restated Stockholders Agreement | Management | For | For |
IONIS PHARMACEUTICALS, INC.
Security | 462222100 | Meeting Type | Annual |
Ticker Symbol | IONS | Meeting Date | 01-Jun-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Spencer R. Berthelsen | For | For | |||||||
2 | Joan E. Herman | For | For | |||||||
3 | B. Lynne Parshall | For | For | |||||||
4 | Joseph H. Wender | For | For | |||||||
2. | To approve, by non-binding vote, executive compensation. | Management | For | For | ||||||
3. | To approve, by non-binding vote, the frequency of future advisory votes on executive compensation. | Management | 1 Year | For | ||||||
4. | To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares. | Management | For | For | ||||||
5. | To ratify increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years. | Management | For | For | ||||||
6. | To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year. | Management | For | For |
IQVIA HOLDINGS INC.
Security | 46266C105 | Meeting Type | Annual |
Ticker Symbol | IQV | Meeting Date | 18-Apr-2023 |
Record Date | 17-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Carol J. Burt | Management | For | For | |||||
1b. | Election of Director: Colleen A. Goggins | Management | For | For | |||||
1c. | Election of Director: Sheila A. Stamps | Management | For | For | |||||
2. | Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay). | Management | For | For | |||||
3. | Approve a Company proposal to amend IQVIA's Certificate of Incorporation to adopt a stockholders' right to request a special stockholders' meeting. | Management | For | For | |||||
4. | If properly presented, a stockholder proposal concerning special stockholder meetings. | Shareholder | For | Against | |||||
5. | If properly presented, a stockholder proposal for separate Chairman and Chief Executive Officer roles. | Shareholder | For | Against | |||||
6. | Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2023. | Management | For | For |
JAZZ PHARMACEUTICALS PLC
Security | G50871105 | Meeting Type | Annual |
Ticker Symbol | JAZZ | Meeting Date | 28-Jul-2022 |
Record Date | 01-Jun-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to hold office until the 2025 Annual General Meeting: Jennifer E. Cook | Management | For | For | |||||
1b. | Election of Director to hold office until the 2025 Annual General Meeting: Patrick G. Enright | Management | For | For | |||||
1c. | Election of Director to hold office until the 2025 Annual General Meeting: Seamus Mulligan | Management | For | For | |||||
1d. | Election of Director to hold office until the 2025 Annual General Meeting: Norbert G. Riedel, Ph.D. | Management | For | For | |||||
2. | To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2022 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration. | Management | For | For | |||||
3. | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. | Management | For | For | |||||
4. | To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. | Management | For | For | |||||
5. | To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 4. | Management | For | For |
JOHNSON & JOHNSON
Security | 478160104 | Meeting Type | Annual |
Ticker Symbol | JNJ | Meeting Date | 27-Apr-2023 |
Record Date | 28-Feb-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Darius Adamczyk | Management | For | For | |||||
1b. | Election of Director: Mary C. Beckerle | Management | For | For | |||||
1c. | Election of Director: D. Scott Davis | Management | For | For | |||||
1d. | Election of Director: Jennifer A. Doudna | Management | For | For | |||||
1e. | Election of Director: Joaquin Duato | Management | For | For | |||||
1f. | Election of Director: Marillyn A. Hewson | Management | For | For | |||||
1g. | Election of Director: Paula A. Johnson | Management | For | For | |||||
1h. | Election of Director: Hubert Joly | Management | For | For | |||||
1I. | Election of Director: Mark B. McClellan | Management | For | For | |||||
1j. | Election of Director: Anne M. Mulcahy | Management | For | For | |||||
1k. | Election of Director: Mark A. Weinberger | Management | For | For | |||||
1l. | Election of Director: Nadja Y. West | Management | For | For | |||||
2. | Advisory Vote to Approve Named Executive Officer Compensation | Management | For | For | |||||
3. | Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation | Management | 1 Year | For | |||||
4. | Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm | Management | For | For | |||||
5. | Proposal Withdrawn (Federal Securities Laws Mandatory Arbitration Bylaw) | Shareholder | Abstain | ||||||
6. | Vaccine Pricing Report | Shareholder | Against | For | |||||
7. | Executive Compensation Adjustment Policy | Shareholder | Against | For | |||||
8. | Impact of Extended Patent Exclusivities on Product Access | Shareholder | Against | For |
KARUNA THERAPEUTICS, INC.
Security | 48576A100 | Meeting Type | Annual |
Ticker Symbol | KRTX | Meeting Date | 20-Jun-2023 |
Record Date | 24-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Bill Meury | Management | For | For | |||||
1b. | Election of Director: Laurie Olson | Management | For | For | |||||
1c. | Election of Director: David Wheadon, M.D. | Management | For | For | |||||
2. | To approve, on an advisory, non-binding basis, the compensation paid to our named executive officers. | Management | For | For | |||||
3. | To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
KURA ONCOLOGY, INC.
Security | 50127T109 | Meeting Type | Annual |
Ticker Symbol | KURA | Meeting Date | 31-May-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class III Director for three-year term: Diane Parks | Management | For | For | |||||
1.2 | Election of Class III Director for three-year term: Mary T. Szela | Management | For | For | |||||
2. | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | Approval, on an advisory basis, of the compensation of our named executive officers during the year ended December 31, 2022. | Management | For | For | |||||
4. | Approval of an amendment to our Amended and Restated 2014 Equity Incentive Plan. | Management | For | For |
LABORATORY CORP. OF AMERICA HOLDINGS
Security | 50540R409 | Meeting Type | Annual |
Ticker Symbol | LH | Meeting Date | 11-May-2023 |
Record Date | 16-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Kerrii B. Anderson | Management | For | For | |||||
1b. | Election of Director: Jean-Luc Bélingard | Management | For | For | |||||
1c. | Election of Director: Jeffrey A. Davis | Management | For | For | |||||
1d. | Election of Director: D. Gary Gilliland, M.D., Ph.D. | Management | For | For | |||||
1e. | Election of Director: Kirsten M. Kliphouse | Management | For | For | |||||
1f. | Election of Director: Garheng Kong, M.D., Ph.D. | Management | For | For | |||||
1g. | Election of Director: Peter M. Neupert | Management | For | For | |||||
1h. | Election of Director: Richelle P. Parham | Management | For | For | |||||
1i. | Election of Director: Adam H. Schechter | Management | For | For | |||||
1j. | Election of Director: Kathryn E. Wengel | Management | For | For | |||||
1k. | Election of Director: R. Sanders Williams, M.D. | Management | For | For | |||||
2. | To approve, by non-binding vote, executive compensation. | Management | For | For | |||||
3. | To recommend by non-binding vote, the frequency of future non-binding votes on executive compensation. | Management | 1 Year | For | |||||
4. | Ratification of the appointment of Deloitte and Touche LLP as Laboratory Corporation of America Holdings' independent registered public accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
5. | Shareholder proposal relating to a policy regarding separation of the roles of Board Chairman and Chief Executive Officer. | Shareholder | For | Against | |||||
6. | Shareholder proposal regarding a Board report on transport of nonhuman primates within the U.S. | Shareholder | Against | For | |||||
7. | Shareholder proposal regarding a Board report on known risks of fulfilling information requests and mitigation strategies. | Shareholder | Against | For |
LANTHEUS HOLDINGS, INC.
Security | 516544103 | Meeting Type | Annual |
Ticker Symbol | LNTH | Meeting Date | 27-Apr-2023 |
Record Date | 06-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director: Ms. Minnie Baylor-Henry | Management | For | For | |||||
1.2 | Election of Class II Director: Mr. Heinz Mäusli | Management | For | For | |||||
1.3 | Election of Class II Director: Ms. Julie McHugh | Management | For | For | |||||
2. | The approval, on an advisory basis, of the compensation paid to our named executive officers. | Management | For | For | |||||
3. | The approval of the Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan. | Management | For | For | |||||
4. | The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
MADRIGAL PHARMACEUTICALS INC.
Security | 558868105 | Meeting Type | Annual |
Ticker Symbol | MDGL | Meeting Date | 15-Jun-2023 |
Record Date | 27-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Re-election of Class I Director: Paul A. Friedman, M.D. | Management | For | For | |||||
1.2 | Re-election of Class I Director: Kenneth M. Bate | Management | For | For | |||||
1.3 | Re-election of Class I Director: James M. Daly | Management | For | For | |||||
2. | To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | Advisory vote to approve executive compensation. | Management | For | For | |||||
4. | Amendment of Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. | Management | For | For |
MARINUS PHARMACEUTICALS, INC.
Security | 56854Q200 | Meeting Type | Annual |
Ticker Symbol | MRNS | Meeting Date | 24-May-2023 |
Record Date | 27-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Tim M. Mayleben | For | For | |||||||
2 | Saraswathy V Nochur PhD | For | For | |||||||
3 | Christine Silverstein | For | For | |||||||
2. | Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement. | Management | For | For |
MCKESSON CORPORATION
Security | 58155Q103 | Meeting Type | Annual |
Ticker Symbol | MCK | Meeting Date | 22-Jul-2022 |
Record Date | 27-May-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director for a one-year term: Richard H. Carmona, M.D. | Management | For | For | |||||
1b. | Election of Director for a one-year term: Dominic J. Caruso | Management | For | For | |||||
1c. | Election of Director for a one-year term: W. Roy Dunbar | Management | For | For | |||||
1d. | Election of Director for a one-year term: James H. Hinton | Management | For | For | |||||
1e. | Election of Director for a one-year term: Donald R. Knauss | Management | For | For | |||||
1f. | Election of Director for a one-year term: Bradley E. Lerman | Management | For | For | |||||
1g. | Election of Director for a one-year term: Linda P. Mantia | Management | For | For | |||||
1h. | Election of Director for a one-year term: Maria Martinez | Management | For | For | |||||
1i. | Election of Director for a one-year term: Susan R. Salka | Management | For | For | |||||
1j. | Election of Director for a one-year term: Brian S. Tyler | Management | For | For | |||||
1k. | Election of Director for a one-year term: Kathleen Wilson-Thompson | Management | For | For | |||||
2. | Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023. | Management | For | For | |||||
3. | Advisory vote on executive compensation. | Management | For | For | |||||
4. | Approval of our 2022 Stock Plan. | Management | For | For | |||||
5. | Approval of Amendment to our 2000 Employee Stock Purchase Plan. | Management | For | For | |||||
6. | Shareholder Proposal on Special Shareholder Meeting Improvement. | Shareholder | Against | For | |||||
7. | Shareholder Proposal on Transparency in Rule 10b5-1 Trading Policy. | Shareholder | Against | For |
MEDPACE HOLDINGS, INC.
Security | 58506Q109 | Meeting Type | Annual |
Ticker Symbol | MEDP | Meeting Date | 19-May-2023 |
Record Date | 23-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Brian T. Carley | For | For | |||||||
2 | F. H. Gwadry-Sridhar | For | For | |||||||
3 | Robert O. Kraft | For | For | |||||||
2. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting. | Management | For | For |
MEDTRONIC PLC
Security | G5960L103 | Meeting Type | Annual |
Ticker Symbol | MDT | Meeting Date | 08-Dec-2022 |
Record Date | 11-Oct-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to hold office until the 2023 Annual General Meeting: Richard H. Anderson | Management | For | For | |||||
1b. | Election of Director to hold office until the 2023 Annual General Meeting: Craig Arnold | Management | For | For | |||||
1c. | Election of Director to hold office until the 2023 Annual General Meeting: Scott C. Donnelly | Management | For | For | |||||
1d. | Election of Director to hold office until the 2023 Annual General Meeting: Lidia L. Fonseca | Management | For | For | |||||
1e. | Election of Director to hold office until the 2023 Annual General Meeting: Andrea J. Goldsmith, Ph.D. | Management | For | For | |||||
1f. | Election of Director to hold office until the 2023 Annual General Meeting: Randall J. Hogan, III | Management | For | For | |||||
1g. | Election of Director to hold office until the 2023 Annual General Meeting: Kevin E. Lofton | Management | For | For | |||||
1h. | Election of Director to hold office until the 2023 Annual General Meeting: Geoffrey S. Martha | Management | For | For | |||||
1i. | Election of Director to hold office until the 2023 Annual General Meeting: Elizabeth G. Nabel, M.D. | Management | For | For | |||||
1j. | Election of Director to hold office until the 2023 Annual General Meeting: Denise M. O'Leary | Management | For | For | |||||
1k. | Election of Director to hold office until the 2023 Annual General Meeting: Kendall J. Powell | Management | For | For | |||||
2. | Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2023 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration. | Management | For | For | |||||
3. | Approving, on an advisory basis, the Company's executive compensation. | Management | For | For | |||||
4. | Renewing the Board of Directors' authority to issue shares under Irish law. | Management | For | For | |||||
5. | Renewing the Board of Directors' authority to opt out of pre-emption rights under Irish law. | Management | For | For | |||||
6. | Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. | Management | For | For |
MERCK & CO., INC.
Security | 58933Y105 | Meeting Type | Annual |
Ticker Symbol | MRK | Meeting Date | 23-May-2023 |
Record Date | 24-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Douglas M. Baker, Jr. | Management | For | For | |||||
1b. | Election of Director: Mary Ellen Coe | Management | For | For | |||||
1c. | Election of Director: Pamela J. Craig | Management | For | For | |||||
1d. | Election of Director: Robert M. Davis | Management | For | For | |||||
1e. | Election of Director: Thomas H. Glocer | Management | For | For | |||||
1f. | Election of Director: Risa J. Lavizzo-Mourey, M.D. | Management | For | For | |||||
1g. | Election of Director: Stephen L. Mayo, Ph.D. | Management | For | For | |||||
1h. | Election of Director: Paul B. Rothman, M.D. | Management | For | For | |||||
1i. | Election of Director: Patricia F. Russo | Management | For | For | |||||
1j. | Election of Director: Christine E. Seidman, M.D. | Management | For | For | |||||
1k. | Election of Director: Inge G. Thulin | Management | For | For | |||||
1l. | Election of Director: Kathy J. Warden | Management | For | For | |||||
1m. | Election of Director: Peter C. Wendell | Management | For | For | |||||
2. | Non-binding advisory vote to approve the compensation of our named executive officers. | Management | For | For | |||||
3. | Non-binding advisory vote to approve the frequency of future votes to approve the compensation of our named executive officers. | Management | 1 Year | For | |||||
4. | Ratification of the appointment of the Company's independent registered public accounting firm for 2023. | Management | For | For | |||||
5. | Shareholder proposal regarding business operations in China. | Shareholder | Against | For | |||||
6. | Shareholder proposal regarding access to COVID-19 products. | Shareholder | Against | For | |||||
7. | Shareholder proposal regarding indirect political spending. | Shareholder | Against | For | |||||
8. | Shareholder proposal regarding patents and access. | Shareholder | Against | For | |||||
9. | Shareholder proposal regarding a congruency report of partnerships with globalist organizations. | Shareholder | Against | For | |||||
10. | Shareholder proposal regarding an independent board chairman. | Shareholder | For | Against |
MEREO BIOPHARMA GROUP PLC
Security | 589492107 | Meeting Type | Special |
Ticker Symbol | MREO | Meeting Date | 18-Nov-2022 |
Record Date | 14-Oct-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | THAT Dr. Peter Fellner, Dr. Anders Ekblom, Dr. Deepika Pakianathan, Dr. Brian Schwartz and Mr. Michael Wyzga be removed from office as directors of the Company with immediate effect. | Management | Against | For | |||||
2. | THAT, conditional upon the passing of resolution 1 above, Dr. Annalisa Jenkins be appointed as director of the Company with immediate effect. | Management | Against | For | |||||
3. | THAT, conditional upon the passing of resolution 1 above, Dr. Daniel Shames be appointed as director of the Company with immediate effect. | Management | Against | For | |||||
4. | THAT, conditional upon the passing of resolution 1 above, Mr. Marc Yoskowitz be appointed as director of the Company with immediate effect. | Management | Against | For | |||||
5. | THAT, conditional upon the passing of resolution 1 above, Mr. Justin Roberts be appointed as director of the Company with immediate effect. | Management | Against | For | |||||
6. | THAT, conditional upon the passing of resolution 1 above, Mr. David Rosen be appointed as director of the Company with immediate effect. | Management | Against | For |
MEREO BIOPHARMA GROUP PLC
Security | 589492107 | Meeting Type | Annual |
Ticker Symbol | MREO | Meeting Date | 22-May-2023 |
Record Date | 10-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | That the annual report and accounts for the financial year ended 31 December 2022, together with the directors' report and independent auditor's report thereon, be received and adopted. | Management | For | For | |||||
2. | That BDO LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented. | Management | For | For | |||||
3. | That the Directors be authorised to determine BDO LLP's remuneration. | Management | For | For | |||||
4. | That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, be approved. | Management | For | For | |||||
5. | That the directors' remuneration policy as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, which takes effect from the end of this AGM, be approved. | Management | For | For | |||||
6. | That Dr. Annalisa Jenkins be re-appointed as a director of the Company. | Management | For | For | |||||
7. | That Justin Roberts be re-appointed as a director of the Company. | Management | For | For | |||||
8. | That Dr. Daniel Shames be re-appointed as a director of the Company. | Management | For | For | |||||
9. | That Marc Yoskowitz be re-appointed as a director of the Company. | Management | For | For | |||||
10. | That the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares in the Company or to grant rights to subscribe for, or to convert securities into, shares in the Company up to a maximum aggregate nominal amount of £2,494,456.76, such authority to expire on 30 June 2026, save that the Company may, before such expiry, make offers or agreements which would, or might, require ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
11. | That, subject to Resolution 10 being passed, the Directors be generally empowered pursuant to section 570 and section 573 of the Act to allot equity securities for cash pursuant to the authority given by Resolution 10 and to sell equity securities held as treasury shares for cash pursuant to section 727 of the Act, in each case as if section 561(1) of the Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment or sale of equity securities up to an ...(due to space limits, see proxy material for full proposal). | Management | For | For |
MIRATI THERAPEUTICS, INC.
Security | 60468T105 | Meeting Type | Annual |
Ticker Symbol | MRTX | Meeting Date | 11-May-2023 |
Record Date | 15-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Charles M. Baum | For | For | |||||||
2 | Bruce L.A. Carter | For | For | |||||||
3 | Julie M. Cherrington | For | For | |||||||
4 | Aaron I. Davis | For | For | |||||||
5 | Faheem Hasnain | For | For | |||||||
6 | Craig Johnson | For | For | |||||||
7 | Maya Martinez-Davis | For | For | |||||||
8 | David Meek | For | For | |||||||
9 | Shalini Sharp | For | For | |||||||
2. | To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement. | Management | For | For | ||||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023. | Management | For | For | ||||||
4. | To approve the amendment to our 2013 Employee Stock Purchase Plan, to increase the aggregate number of shares of our common stock reserved for issuance under such plan by 750,000 shares. | Management | For | For |
MODERNA, INC.
Security | 60770K107 | Meeting Type | Annual |
Ticker Symbol | MRNA | Meeting Date | 03-May-2023 |
Record Date | 08-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Stephen Berenson | For | For | |||||||
2 | Sandra Horning, M.D. | For | For | |||||||
3 | Paul Sagan | For | For | |||||||
2. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | ||||||
3. | To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2023. | Management | For | For | ||||||
4. | To vote on a shareholder proposal requesting a report on transferring intellectual property. | Shareholder | Against | For |
MOLINA HEALTHCARE, INC.
Security | 60855R100 | Meeting Type | Annual |
Ticker Symbol | MOH | Meeting Date | 03-May-2023 |
Record Date | 08-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to hold office until the 2024 Annual Meeting: Barbara L. Brasier | Management | For | For | |||||
1b. | Election of Director to hold office until the 2024 Annual Meeting: Daniel Cooperman | Management | For | For | |||||
1c. | Election of Director to hold office until the 2024 Annual Meeting: Stephen H. Lockhart | Management | For | For | |||||
1d. | Election of Director to hold office until the 2024 Annual Meeting: Steven J. Orlando | Management | For | For | |||||
1e. | Election of Director to hold office until the 2024 Annual Meeting: Ronna E. Romney | Management | For | For | |||||
1f. | Election of Director to hold office until the 2024 Annual Meeting: Richard M. Schapiro | Management | For | For | |||||
1g. | Election of Director to hold office until the 2024 Annual Meeting: Dale B. Wolf | Management | For | For | |||||
1h. | Election of Director to hold office until the 2024 Annual Meeting: Richard C. Zoretic | Management | For | For | |||||
1i. | Election of Director to hold office until the 2024 Annual Meeting: Joseph M. Zubretsky | Management | For | For | |||||
2. | To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | |||||
3. | To conduct an advisory vote on the frequency of a stockholder vote on the compensation of our named executive officers. | Management | 1 Year | For | |||||
4. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023. | Management | For | For |
NEUROCRINE BIOSCIENCES, INC.
Security | 64125C109 | Meeting Type | Annual |
Ticker Symbol | NBIX | Meeting Date | 17-May-2023 |
Record Date | 20-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Kevin C. Gorman, Ph.D. | For | For | |||||||
2 | Gary A. Lyons | For | For | |||||||
3 | Johanna Mercier | For | For | |||||||
2. | Advisory vote to approve the compensation paid to the Company's named executive officers. | Management | For | For | ||||||
3. | Advisory vote on the frequency of advisory votes to approve the compensation paid to the Company's named executive officers. | Management | 1 Year | For | ||||||
4. | To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 6,600,000 shares. | Management | Against | Against | ||||||
5. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
NEXGEL, INC.
Security | 65344E107 | Meeting Type | Annual |
Ticker Symbol | NXGL | Meeting Date | 30-Aug-2022 |
Record Date | 06-Jul-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Adam Levy | For | For | |||||||
2 | Steven Glassman | For | For | |||||||
3 | Yaakov Spinrad | For | For | |||||||
4 | David Stefansky | For | For | |||||||
5 | Nachum Stein | For | For | |||||||
6 | Miranda J. Toledano | For | For | |||||||
7 | Dr. J.B. Zeldis MD, PhD | For | For | |||||||
2. | Proposal to approve an amendment to our Restated Certificate of Incorporation (the "Charter"), in substantially the form attached to the proxy statement as Annex A, reduce the total number of authorized shares of our common stock, par value $0.001 per share, each from 750,000,000 to 25,000,000. | Management | For | For | ||||||
3. | Advisory vote on the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice. | Management | For | For | ||||||
4. | Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers. | Management | 1 Year | Against | ||||||
5. | Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2022 fiscal year. | Management | For | For |
NEXGEL, INC.
Security | 65344E107 | Meeting Type | Annual |
Ticker Symbol | NXGL | Meeting Date | 06-Jun-2023 |
Record Date | 11-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Adam Levy | For | For | |||||||
2 | Steven Glassman | For | For | |||||||
3 | Scott R. Henry | For | For | |||||||
4 | David Stefansky | For | For | |||||||
5 | Nachum Stein | For | For | |||||||
6 | Miranda J. Toledano | For | For | |||||||
7 | Dr. J.B. Zeldis MD, PhD | For | For | |||||||
2. | Proposal to approve the Third Amendment to the NexGel, Inc. 2019 Long-Term Incentive Plan to increase the total number of shares of common stock authorized for issuance under such plan by 300,000, to a total of 871,429 shares. | Management | For | For | ||||||
3. | Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2023 fiscal year. | Management | For | For |
NOVAVAX, INC.
Security | 670002401 | Meeting Type | Annual |
Ticker Symbol | NVAX | Meeting Date | 11-Jul-2023 |
Record Date | 18-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: John C. Jacobs | Management | For | For | |||||
1b. | Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Gregg H. Alton, J.D. | Management | For | For | |||||
1c. | Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Richard J. Rodgers | Management | For | For | |||||
2. | The approval, on an advisory basis, of the compensation paid to our Named Executive Officers. | Management | For | For | |||||
3. | The approval, on an advisory basis, of holding future executive compensation advisory votes every three years, every two years, or every year. | Management | 1 Year | For | |||||
4. | Amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended, to reflect Delaware law provisions allowing officer exculpation. | Management | For | For | |||||
5. | Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended to increase the number of shares of common stock available for issuance thereunder by 6,170,000 shares. | Management | Against | Against | |||||
6. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
OCULIS HOLDING AG
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 8-Jul-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1 | Change of Designation of the Existing Series C Preferred Shares and Revision of the Articles of Association | Management | For | For | |||||
2. | Ordinary Share Capital Increase | Management | For | For | |||||
3. | Conditional Share Capital Increase | Management | For | For | |||||
4. | Election of Member to the Board of Directors | Management | For | For |
PARTHENON THERAPEUTICS, INC
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 21-Feb-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1 | Pursuant to Section 1.2(e) of the Voting Agreement, Laurent Audoly be, and he hereby is, removed as the CEO Director and as a member of the Board, in each case with immediate effect | Management | For | For | |||||
2. | Following the removal of Dr. Audoly as the CEO Director pursuant to the foregoing, the CEO Director seat shall remain vacant in accordance with Section 1.2(e) of the Voting Agreement until a new Chief Executive Officer of the Company is duly qualified and appointed | Management | For | For | |||||
3. | The proper officers of the Company be, and each of them hereby is, authorized and directed, in the name of and on behalf of the Company, to prepare or cause to be prepared and to execute, deliver, verify, acknowledge, file or record any documents, instruments, certificates, statements, papers, or any amendments thereto, as in their sole judgment may be necessary, appropriate or advisable in order to effect the foregoing resolutions, and to take such further steps and do all such further acts or things as in their sole judgment may be necessary, appropriate or advisable to carry out the foregoing resolutions | Management | For | For | |||||
4. | The authority and power given hereunder be deemed retroactive and any and all actions previously taken by any officer or director of the Company in connection with these resolutions are hereby ratified and approved | Management | For | For |
PERRIGO COMPANY PLC
Security | G97822103 | Meeting Type | Annual |
Ticker Symbol | PRGO | Meeting Date | 04-May-2023 |
Record Date | 06-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director to hold office until the 2024 Annual General Meeting: Bradley A. Alford | Management | For | For | |||||
1B. | Election of Director to hold office until the 2024 Annual General Meeting: Orlando D. Ashford | Management | For | For | |||||
1C. | Election of Director to hold office until the 2024 Annual General Meeting: Katherine C. Doyle | Management | For | For | |||||
1D. | Election of Director to hold office until the 2024 Annual General Meeting: Adriana Karaboutis | Management | For | For | |||||
1E. | Election of Director to hold office until the 2024 Annual General Meeting: Murray S. Kessler | Management | For | For | |||||
1F. | Election of Director to hold office until the 2024 Annual General Meeting: Jeffrey B. Kindler | Management | For | For | |||||
1G. | Election of Director to hold office until the 2024 Annual General Meeting: Erica L. Mann | Management | For | For | |||||
1H. | Election of Director to hold office until the 2024 Annual General Meeting: Albert A. Manzone | Management | For | For | |||||
1I. | Election of Director to hold office until the 2024 Annual General Meeting: Donal O'Connor | Management | For | For | |||||
1J. | Election of Director to hold office until the 2024 Annual General Meeting: Geoffrey M. Parker | Management | For | For | |||||
2. | Ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company's independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor | Management | For | For | |||||
3. | Advisory vote on executive compensation | Management | For | For | |||||
4. | Advisory vote on the frequency of future advisory votes on executive compensation | Management | 1 Year | For | |||||
5. | Renew the Board's authority to issue shares under Irish law | Management | For | For | |||||
6. | Renew the Board's authority to opt-out of statutory pre-emption rights under Irish law | Management | For | For | |||||
7. | Approve the creation of distributable reserves by reducing some or all of the Company's share premium | Management | For | For |
PFIZER INC.
Security | 717081103 | Meeting Type | Annual |
Ticker Symbol | PFE | Meeting Date | 27-Apr-2023 |
Record Date | 01-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Ronald E. Blaylock | Management | For | For | |||||
1b. | Election of Director: Albert Bourla | Management | For | For | |||||
1c. | Election of Director: Susan Desmond-Hellmann | Management | For | For | |||||
1d. | Election of Director: Joseph J. Echevarria | Management | For | For | |||||
1e. | Election of Director: Scott Gottlieb | Management | For | For | |||||
1f. | Election of Director: Helen H. Hobbs | Management | For | For | |||||
1g. | Election of Director: Susan Hockfield | Management | For | For | |||||
1h. | Election of Director: Dan R. Littman | Management | For | For | |||||
1i. | Election of Director: Shantanu Narayen | Management | For | For | |||||
1j. | Election of Director: Suzanne Nora Johnson | Management | For | For | |||||
1k. | Election of Director: James Quincey | Management | For | For | |||||
1l. | Election of Director: James C. Smith | Management | For | For | |||||
2. | Ratify the selection of KPMG LLP as independent registered public accounting firm for 2023 | Management | For | For | |||||
3. | 2023 advisory approval of executive compensation | Management | For | For | |||||
4. | Advisory vote on frequency of future advisory votes to approve executive compensation | Management | 1 Year | For | |||||
5. | Shareholder proposal regarding ratification of termination pay | Shareholder | Against | For | |||||
6. | Shareholder proposal regarding independent board chairman policy | Shareholder | For | Against | |||||
7. | Shareholder proposal regarding transfer of intellectual property to potential COVID-19 manufacturers feasibility report | Shareholder | Against | For | |||||
8. | Shareholder proposal regarding impact of extended patent exclusivities on product access report | Shareholder | Against | For | |||||
9. | Shareholder proposal regarding political contributions congruency report | Shareholder | Against | For |
PRAXIS PRECISION MEDICINES, INC.
Security | 74006W108 | Meeting Type | Annual |
Ticker Symbol | PRAX | Meeting Date | 12-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Gregory Norden | Management | For | For | |||||
1b. | Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Marcio Souza | Management | For | For | |||||
1c. | Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: William Young | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | To approve on a non-binding, advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2023 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | Management | For | For |
PRECISION BIOSCIENCES, INC.
Security | 74019P108 | Meeting Type | Annual |
Ticker Symbol | DTIL | Meeting Date | 04-May-2023 |
Record Date | 09-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Michael Amoroso | For | For | |||||||
2 | Geno Germano | For | For | |||||||
2. | Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2023. | Management | For | For |
PRIOTHERA LIMITED
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 5-Dec-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Notice of Appointment of Authorized Person | Management | For | For |
PROMETHEUS BIOSCIENCES, INC.
Security | 74349U108 | Meeting Type | Special |
Ticker Symbol | RXDX | Meeting Date | 15-Jun-2023 |
Record Date | 15-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of April 15, 2023, by and among Merck & Co., Inc., a New Jersey corporation ("Merck"), Splash Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Merck ("Merger Sub"), and Prometheus Biosciences, Inc., a Delaware corporation ("Prometheus"), pursuant to which Merger Sub will be merged with and into Prometheus, with Prometheus surviving as a wholly owned subsidiary of Merck (the "Merger"). | Management | For | For | |||||
2. | To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Prometheus' named executive officers that is based on or otherwise relates to the Merger. | Management | For | For | |||||
3. | To approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes in person or by proxy to approve the proposal to adopt the Merger Agreement at the time of the special meeting. | Management | For | For |
PYXIS ONCOLOGY, INC.
Security | 747324101 | Meeting Type | Annual |
Ticker Symbol | PYXS | Meeting Date | 13-Jun-2023 |
Record Date | 20-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Rachel Humphrey, M.D. | Management | For | For | |||||
1.2 | Election of Director: Freda Lewis-Hall, M.D. | Management | For | For | |||||
1.3 | Election of Director: Thomas Civik | Management | For | For | |||||
2. | Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2023 | Management | For | For |
QUELL THERAPEUTICS
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 2-Jun-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the Limited Equity Incentive Plan | Management | For | For | |||||
2. | Approval of the new articles of association of the Company (the "New Articles") in substitution for, and to the entire exclusion of, the current articles of association of the Company | Management | For | For |
RALLYBIO CORPORATION
Security | 75120L100 | Meeting Type | Annual |
Ticker Symbol | RLYB | Meeting Date | 17-May-2023 |
Record Date | 20-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director: Helen M. Boudreau | Management | For | For | |||||
1.2 | Election of Class II Director: Lucian Iancovici | Management | For | For | |||||
1.3 | Election of Class II Director: Christine A. Nash | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm. | Management | For | For |
REATA PHARMACEUTICALS, INC.
Security | 75615P103 | Meeting Type | Annual |
Ticker Symbol | RETA | Meeting Date | 07-Jun-2023 |
Record Date | 12-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director to serve until the 2026 Annual Meeting: Martin W. Edwards, M.D. | Management | For | For | |||||
1.2 | Election of Class II Director to serve until the 2026 Annual Meeting: R. Kent McGaughy, Jr. | Management | For | For | |||||
1.3 | Election of Class II Director to serve until the 2026 Annual Meeting: Christy J. Oliger | Management | For | For | |||||
2. | An advisory (non-binding) vote on a resolution to approve the compensation of our named executive officers. | Management | For | For | |||||
3. | The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
RECODE THERAPEUTICS
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 6-Jan-2023 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment No. 2 to Series B Preferred Stock Purchase Agreement | Management | For | For |
REGENERON PHARMACEUTICALS, INC.
Security | 75886F107 | Meeting Type | Annual |
Ticker Symbol | REGN | Meeting Date | 09-Jun-2023 |
Record Date | 11-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Joseph L. Goldstein, M.D. | Management | For | For | |||||
1b. | Election of Director: Christine A. Poon | Management | For | For | |||||
1c. | Election of Director: Craig B. Thompson, M.D. | Management | For | For | |||||
1d. | Election of Director: Huda Y. Zoghbi, M.D. | Management | For | For | |||||
2. | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
3. | Proposal to approve, on an advisory basis, executive compensation. | Management | For | For | |||||
4. | Proposal to approve, on an advisory basis, the frequency of future advisory votes on executive compensation. | Management | 1 Year | For | |||||
5. | Non-binding shareholder proposal, if properly presented, requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property. | Shareholder | Against | For |
SAREPTA THERAPEUTICS, INC.
Security | 803607100 | Meeting Type | Annual |
Ticker Symbol | SRPT | Meeting Date | 08-Jun-2023 |
Record Date | 14-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director to hold office until the 2025 Annual Meeting: Richard J. Barry | Management | For | For | |||||
1.2 | Election of Class II Director to hold office until the 2025 Annual Meeting: M. Kathleen Behrens, Ph.D. | Management | For | For | |||||
1.3 | Election of Class II Director to hold office until the 2025 Annual Meeting: Stephen L. Mayo, Ph. D. | Management | For | For | |||||
1.4 | Election of Class II Director to hold office until the 2025 Annual Meeting: Claude Nicaise, M.D. | Management | For | For | |||||
2. | Advisory vote to approve, on a non-binding basis, named executive officer compensation | Management | For | For | |||||
3. | Approve an amendment to the Company's 2018 Equity Incentive Plan (the "2018 Plan") to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 13,187,596 shares | Management | For | For | |||||
4. | Approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016 and amended on June 6, 2019) (the "2016 ESPP") to increase the number of shares of our common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,400,000 shares | Management | For | For | |||||
5. | Advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years | Management | 1 Year | For | |||||
6. | Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2023 | Management | For | For |
SCHOLAR ROCK HOLDING CORPORATION
Security | 80706P103 | Meeting Type | Annual |
Ticker Symbol | SRRK | Meeting Date | 21-Jun-2023 |
Record Date | 24-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | David Hallal | For | For | |||||||
2 | Kristina Burow | For | For | |||||||
3 | Michael Gilman Ph.D | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
SEAGEN INC.
Security | 81181C104 | Meeting Type | Special |
Ticker Symbol | SGEN | Meeting Date | 30-May-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To consider and vote on the proposal to adopt the Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "merger agreement"), dated March 12, 2023, by and among Seagen Inc. ("Seagen"), Pfizer Inc. ("Pfizer") and Aris Merger Sub, Inc., a wholly-owned subsidiary of Pfizer ("Merger Sub"), and pursuant to which Merger Sub will be merged with and into Seagen, with Seagen surviving the merger as a wholly-owned subsidiary of Pfizer (the "merger" and such proposal the "merger agreement proposal"). | Management | For | For | |||||
2. | To consider and vote on the proposal to approve, on a non-binding, advisory basis, certain compensation arrangements for Seagen's named executive officers in connection with the merger (the "compensation proposal"). | Management | For | For |
SEAGEN INC.
Security | 81181C104 | Meeting Type | Annual |
Ticker Symbol | SGEN | Meeting Date | 31-May-2023 |
Record Date | 03-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class I Director: David W. Gryska | Management | For | For | |||||
1b. | Election of Class I Director: John A. Orwin | Management | For | For | |||||
1c. | Election of Class I Director: Alpna H. Seth, Ph.D. | Management | For | For | |||||
2. | Approve, on an advisory basis, the compensation of Seagen's named executive officers as disclosed in the accompanying proxy statement. | Management | For | For | |||||
3. | Indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Seagen's named executive officers. | Management | 1 Year | For | |||||
4. | Approve the amendment and restatement of the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 5,190,000 shares. | Management | For | For | |||||
5. | Ratify the appointment of PricewaterhouseCoopers LLP as Seagen's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For |
SPDR SERIES TRUST
Security | 78464A870 | Meeting Type | Special |
Ticker Symbol | XBI | Meeting Date | 20-Oct-2022 |
Record Date | 20-Jul-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Clare S. Richer | For | For | |||||||
2 | Sandra G. Sponem | For | For | |||||||
3 | Kristi L. Rowsell | For | For | |||||||
4 | Gunjan Chauhan | For | For | |||||||
5 | Carolyn M. Clancy | For | For |
STRYKER CORPORATION
Security | 863667101 | Meeting Type | Annual |
Ticker Symbol | SYK | Meeting Date | 10-May-2023 |
Record Date | 13-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Mary K. Brainerd | Management | For | For | |||||
1b. | Election of Director: Giovanni Caforio, M.D. | Management | For | For | |||||
1c. | Election of Director: Srikant M. Datar, Ph.D. | Management | For | For | |||||
1d. | Election of Director: Allan C. Golston | Management | For | For | |||||
1e. | Election of Director: Kevin A. Lobo (Chair of the Board, Chief Executive Officer and President) | Management | For | For | |||||
1f. | Election of Director: Sherilyn S. McCoy (Lead Independent Director) | Management | For | For | |||||
1g. | Election of Director: Andrew K. Silvernail | Management | For | For | |||||
1h. | Election of Director: Lisa M. Skeete Tatum | Management | For | For | |||||
1i. | Election of Director: Ronda E. Stryker | Management | For | For | |||||
1j. | Election of Director: Rajeev Suri | Management | For | For | |||||
2. | Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2023. | Management | For | For | |||||
3. | Advisory Vote to Approve Named Executive Officer Compensation. | Management | For | For | |||||
4. | Advisory Vote on the Frequency of Future Advisory Votes on Named Executive Officer Compensation. | Management | 1 Year | For | |||||
5. | Shareholder Proposal on Political Disclosure. | Shareholder | Against | For |
SUTRO BIOPHARMA, INC.
Security | 869367102 | Meeting Type | Annual |
Ticker Symbol | STRO | Meeting Date | 08-Jun-2023 |
Record Date | 20-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | William J. Newell | For | For | |||||||
2 | Connie Matsui | For | For | |||||||
3 | James Panek | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | ||||||
4. | To approve the amendment and restatement of our restated certificate of incorporation to permit the exculpation of our officers from personal liability for certain breaches of the duty of care. | Management | For | For |
SYNDAX PHARMACEUTICALS, INC
Security | 87164F105 | Meeting Type | Annual |
Ticker Symbol | SNDX | Meeting Date | 17-May-2023 |
Record Date | 22-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Pierre Legault | Management | For | For | |||||
1.2 | Election of Director: Michael A. Metzger | Management | For | For | |||||
2. | To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the 2023 proxy statement. | Management | For | For | |||||
3. | To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. | Management | For | For | |||||
4. | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares. | Management | For | For |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Security | 881624209 | Meeting Type | Annual |
Ticker Symbol | TEVA | Meeting Date | 15-Jun-2023 |
Record Date | 10-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Dr. Sol J. Barer | Management | For | For | |||||
1B. | Election of Director: M. Braverman-Blumenstyk | Management | For | For | |||||
1C. | Election of Director: Janet S. Vergis | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. | Management | For | For | |||||
3. | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders. | Management | For | For |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Security | 881624209 | Meeting Type | Annual |
Ticker Symbol | TEVA | Meeting Date | 15-Jun-2023 |
Record Date | 08-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Dr. Sol J. Barer | Management | For | For | |||||
1B. | Election of Director: M. Braverman-Blumenstyk | Management | For | For | |||||
1C. | Election of Director: Janet S. Vergis | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. | Management | For | For | |||||
3. | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders. | Management | For | For |
THE CIGNA GROUP
Security | 125523100 | Meeting Type | Annual |
Ticker Symbol | CI | Meeting Date | 26-Apr-2023 |
Record Date | 07-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: David M. Cordani | Management | For | For | |||||
1b. | Election of Director: William J. DeLaney | Management | For | For | |||||
1c. | Election of Director: Eric J. Foss | Management | For | For | |||||
1d. | Election of Director: Retired Maj. Gen. Elder Granger, M.D. | Management | For | For | |||||
1e. | Election of Director: Neesha Hathi | Management | For | For | |||||
1f. | Election of Director: George Kurian | Management | For | For | |||||
1g. | Election of Director: Kathleen M. Mazzarella | Management | For | For | |||||
1h. | Election of Director: Mark B. McClellan, M.D., Ph.D. | Management | For | For | |||||
1i. | Election of Director: Kimberly A. Ross | Management | For | For | |||||
1j. | Election of Director: Eric C. Wiseman | Management | For | For | |||||
1k. | Election of Director: Donna F. Zarcone | Management | For | For | |||||
2. | Advisory approval of The Cigna Group's executive compensation | Management | For | For | |||||
3. | Advisory approval of the frequency of future advisory votes on executive compensation | Management | 1 Year | For | |||||
4. | Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group's independent registered public accounting firm for 2023 | Management | For | For | |||||
5. | Approval of an amendment to our Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law | Management | For | For | |||||
6. | Shareholder proposal - Special shareholder meeting improvement | Shareholder | Against | For | |||||
7. | Shareholder proposal - Political contributions report | Shareholder | Against | For |
THERMO FISHER SCIENTIFIC INC.
Security | 883556102 | Meeting Type | Annual |
Ticker Symbol | TMO | Meeting Date | 24-May-2023 |
Record Date | 27-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Marc N. Casper | Management | For | For | |||||
1b. | Election of Director: Nelson J. Chai | Management | For | For | |||||
1c. | Election of Director: Ruby R. Chandy | Management | For | For | |||||
1d. | Election of Director: C. Martin Harris | Management | For | For | |||||
1e. | Election of Director: Tyler Jacks | Management | For | For | |||||
1f. | Election of Director: R. Alexandra Keith | Management | For | For | |||||
1g. | Election of Director: James C. Mullen | Management | For | For | |||||
1h. | Election of Director: Lars R. Sørensen | Management | For | For | |||||
1i. | Election of Director: Debora L. Spar | Management | For | For | |||||
1j. | Election of Director: Scott M. Sperling | Management | For | For | |||||
1k. | Election of Director: Dion J. Weisler | Management | For | For | |||||
2. | An advisory vote to approve named executive officer compensation. | Management | For | For | |||||
3. | An advisory vote on the frequency of future named executive officer advisory votes. | Management | 1 Year | For | |||||
4. | Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2023. | Management | For | For | |||||
5. | Approval of the Company's Amended and Restated 2013 Stock Incentive Plan. | Management | For | For | |||||
6. | Approval of the Company's 2023 Global Employee Stock Purchase Plan. | Management | For | For |
THESEUS PHARMACEUTICALS, INC.
Security | 88369M101 | Meeting Type | Annual |
Ticker Symbol | THRX | Meeting Date | 09-Jun-2023 |
Record Date | 13-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Carl Gordon | For | For | |||||||
2 | Michael Rome | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law. | Management | For | For |
TRAVERE THERAPEUTICS INC.
Security | 89422G107 | Meeting Type | Annual |
Ticker Symbol | TVTX | Meeting Date | 17-May-2023 |
Record Date | 21-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Roy Baynes | For | For | |||||||
2 | Suzanne Bruhn | For | For | |||||||
3 | Timothy Coughlin | For | For | |||||||
4 | Eric Dube | For | For | |||||||
5 | Gary Lyons | For | For | |||||||
6 | Jeffrey Meckler | For | For | |||||||
7 | John Orwin | For | For | |||||||
8 | Sandra Poole | For | For | |||||||
9 | Ron Squarer | For | For | |||||||
10 | Ruth Williams-Brinkley | For | For | |||||||
2. | To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000 shares. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the compensation of the Company's named executive officers. | Management | For | For | ||||||
4. | To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. | Management | For | For |
TSCAN THERAPEUTICS, INC.
Security | 89854M101 | Meeting Type | Annual |
Ticker Symbol | TCRX | Meeting Date | 13-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Katina Dorton, JD, MBA | For | For | |||||||
2. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 | Management | For | For | ||||||
3. | To approve an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of shares of voting common stock authorized for issuance under the plan by 7,500,000 shares | Management | For | For |
ULTRAGENYX PHARMACEUTICAL INC.
Security | 90400D108 | Meeting Type | Annual |
Ticker Symbol | RARE | Meeting Date | 07-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Emil D. Kakkis, M.D., Ph.D. | Management | For | For | |||||
1b. | Election of Director: Shehnaaz Suliman, M.D. | Management | For | For | |||||
1c. | Election of Director: Daniel G. Welch | Management | For | For | |||||
2. | Approval of the 2023 Incentive Plan. | Management | For | For | |||||
3. | Approval of the Amended & Restated Employee Stock Purchase Plan. | Management | For | For | |||||
4. | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | |||||
5. | Advisory (non-binding) vote to approve the compensation of our named executive officers. | Management | For | For |
UNIQURE N.V.
Security | N90064101 | Meeting Type | Annual |
Ticker Symbol | QURE | Meeting Date | 13-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results. | Management | For | For | |||||
2. | Resolution to discharge liability of the members of the Board. | Management | For | For | |||||
3. | Reappointment of Madhavan Balachandran as non-executive director. | Management | For | For | |||||
4. | Reappointment of Jack Kaye as non-executive director. | Management | For | For | |||||
5. | Reappointment of Leonard Post as non-executive director. | Management | For | For | |||||
6. | Reappointment of Jeremy Springhorn as non-executive director. | Management | For | For | |||||
7. | Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options. | Management | For | For | |||||
8. | Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares. | Management | For | For | |||||
9. | Resolution to reauthorize the Board to repurchase Ordinary Shares. | Management | For | For | |||||
10. | Resolution to appoint KPMG as external auditors of the Company for the financial year 2023. | Management | For | For | |||||
11. | Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. | Management | For | For | |||||
12. | Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan. | Management | For | For |
UNIQURE N.V.
Security | N90064101 | Meeting Type | Annual |
Ticker Symbol | QURE | Meeting Date | 13-Jun-2023 |
Record Date | 16-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results. | Management | For | For | |||||
2. | Resolution to discharge liability of the members of the Board. | Management | For | For | |||||
3. | Reappointment of Madhavan Balachandran as non-executive director. | Management | For | For | |||||
4. | Reappointment of Jack Kaye as non-executive director. | Management | For | For | |||||
5. | Reappointment of Leonard Post as non-executive director. | Management | For | For | |||||
6. | Reappointment of Jeremy Springhorn as non-executive director. | Management | For | For | |||||
7. | Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options. | Management | For | For | |||||
8. | Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares. | Management | For | For | |||||
9. | Resolution to reauthorize the Board to repurchase Ordinary Shares. | Management | For | For | |||||
10. | Resolution to appoint KPMG as external auditors of the Company for the financial year 2023. | Management | For | For | |||||
11. | Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. | Management | For | For | |||||
12. | Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan. | Management | For | For |
UNITED THERAPEUTICS CORPORATION
Security | 91307C102 | Meeting Type | Annual |
Ticker Symbol | UTHR | Meeting Date | 26-Jun-2023 |
Record Date | 27-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Christopher Causey | Management | For | For | |||||
1b. | Election of Director: Raymond Dwek | Management | For | For | |||||
1c. | Election of Director: Richard Giltner | Management | For | For | |||||
1d. | Election of Director: Katherine Klein | Management | For | For | |||||
1e. | Election of Director: Ray Kurzweil | Management | For | For | |||||
1f. | Election of Director: Linda Maxwell | Management | For | For | |||||
1g. | Election of Director: Nilda Mesa | Management | For | For | |||||
1h. | Election of Director: Judy Olian | Management | For | For | |||||
1i. | Election of Director: Christopher Patusky | Management | For | For | |||||
1j. | Election of Director: Martine Rothblatt | Management | For | For | |||||
1k. | Election of Director: Louis Sullivan | Management | For | For | |||||
1l. | Election of Director: Tommy Thompson | Management | For | For | |||||
2. | Advisory resolution to approve executive compensation. | Management | For | For | |||||
3. | Advisory vote on the frequency of future advisory votes on executive compensation. | Management | 1 Year | For | |||||
4. | Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan. | Management | For | For | |||||
5. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023. | Management | For | For |
UNITEDHEALTH GROUP INCORPORATED
Security | 91324P102 | Meeting Type | Annual |
Ticker Symbol | UNH | Meeting Date | 05-Jun-2023 |
Record Date | 10-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Timothy Flynn | Management | For | For | |||||
1b. | Election of Director: Paul Garcia | Management | For | For | |||||
1c. | Election of Director: Kristen Gil | Management | For | For | |||||
1d. | Election of Director: Stephen Hemsley | Management | For | For | |||||
1e. | Election of Director: Michele Hooper | Management | For | For | |||||
1f. | Election of Director: F. William McNabb III | Management | For | For | |||||
1g. | Election of Director: Valerie Montgomery Rice, M.D. | Management | For | For | |||||
1h. | Election of Director: John Noseworthy, M.D. | Management | For | For | |||||
1i. | Election of Director: Andrew Witty | Management | For | For | |||||
2. | Advisory approval of the Company's executive compensation. | Management | For | For | |||||
3. | Advisory approval of the frequency of holding future say-on-pay votes. | Management | 1 Year | For | |||||
4. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023. | Management | For | For | |||||
5. | If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal seeking a third-party racial equity audit. | Shareholder | Against | For | |||||
6. | If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal requiring a political contributions congruency report. | Shareholder | Against | For | |||||
7. | If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal seeking shareholder ratification of termination pay. | Shareholder | Against | For |
VAXCYTE, INC.
Security | 92243G108 | Meeting Type | Annual |
Ticker Symbol | PCVX | Meeting Date | 13-Jun-2023 |
Record Date | 17-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Halley Gilbert, J.D. | For | For | |||||||
2 | Michael E Kamarck Ph.D. | For | For | |||||||
3 | Grant E Pickering M.B.A | For | For | |||||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. | Management | For | For | ||||||
3. | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. | Management | For | For |
VECTIVBIO HOLDING AG
Security | H9060V101 | Meeting Type | Special |
Ticker Symbol | VECT | Meeting Date | 09-Dec-2022 |
Record Date | 31-Oct-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Wouter Joustra - The Board of Directors proposes to elect Wouter Joustra as a new member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting of the Company. | Management | For | For |
VECTIVBIO HOLDING AG
Security | H9060V101 | Meeting Type | Annual |
Ticker Symbol | VECT | Meeting Date | 01-Jun-2023 |
Record Date | 02-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Approval of the 2022 Statutory Financial Statements and Consolidated Financial Statements - The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2022 be approved. | Management | For | For | |||||
1.2 | Advisory Vote on the 2022 Compensation Report - The Board of Directors proposes that the 2022 Compensation Report be endorsed in a non-binding advisory vote. | Management | For | For | |||||
2 | Appropriation of 2022 Financial Results - The Board of Directors proposes that the loss of the Company be carried forward as follows: Loss carried forward from the financial year 2021 CHF -28,435,076 Loss for the financial year 2022 CHF -36,211,404 Loss to be carried forward CHF -64,646,480. | Management | For | For | |||||
3 | Discharge of the Board of Directors and of the Executive Committee - The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2022. | Management | For | For | |||||
4.1 | Re-election of Thomas Woiwode (as Chairman and member of the Board of Directors) - The Board of Directors proposes to re-elect Thomas Woiwode as Chairman and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.2 | Re-election of Sandip Kapadia - The Board of Directors proposes to re-elect Sandip Kapadia as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.3 | Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.4 | Re-election of Luca Santarelli - The Board of Directors proposes to re-elect Luca Santarelli as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.5 | Re-election of Hans Schikan - The Board of Directors proposes to re-elect Hans Schikan as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.6 | Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
4.7 | Re-election of Wouter Joustra - The Board of Directors proposes to re-elect Wouter Joustra as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
5.1 | Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
5.2 | Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
5.3 | Re-election of Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
6 | Re-election of the Statutory Auditors - The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re-elected as the Company's statutory auditors for the financial year 2023. | Management | For | For | |||||
7 | Re-election of the Independent Proxy - The Board of Directors proposes that Buis Bürgi AG, Zurich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2024 Annual General Meeting. | Management | For | For | |||||
8.1 | Approval of the Maximum Aggregate Amount of Compensation of the Board of Directors - The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting of CHF 2,200,000 be approved. | Management | For | For | |||||
8.2 | Approval of the Maximum Aggregate Amount of Compensation of the Executive Committee - The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2024 of CHF 18,500,000 be approved. | Management | For | For | |||||
9 | Introduction of a Capital Range - The Board of Directors proposes to cancel the existing authorized share capital pursuant to article 3a of the Articles of Association and to replace it with a capital range ranging from CHF 3,369,589.50 (lower limit) to CHF 5,054,384.25 (upper limit) as set forth in the invitation to the 2023 Annual General Meeting. | Management | For | For | |||||
10 | Increase of the Conditional Share Capital for Participation Programs - The Board of Directors proposes (i) that the Company's conditional share capital for participation programs be increased by CHF 692,576.75 to the maximum amount of CHF 1,233,908.75, allowing the issuance of up to 24,678,175 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles ...(due to space limits, see proxy material for full proposal). | Management | Against | Against | |||||
11a | Amendments to the Articles of Association - Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees - The Board of Directors proposes to amend articles 4 and 5 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting. | Management | For | For | |||||
11b | Amendments to the Articles of Association - Shareholder Rights, General Meeting of Shareholders, Notices and Communications - The Board of Directors proposes to amend articles 7, 8, 9, 10, 13, 24 and 34 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting. | Management | For | For | |||||
11c | Amendments to the Articles of Association - Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company - The Board of Directors proposes to amend articles 18, 19, 26, 27 and 29 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting. | Management | For | For | |||||
11d | Amendments to the Articles of Association - Jurisdiction Clause - The Board of Directors proposes to introduce a new article 35 to our Articles of Association as set forth in the invitation to the 2023 Annual General Meeting. | Management | For | For |
VECTIVBIO HOLDING AG
Security | H9060V101 | Meeting Type | Special |
Ticker Symbol | VECT | Meeting Date | 26-Jun-2023 |
Record Date | 22-May-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Removal of the Restrictions on Registration and Exercise of Voting Rights (Conditional Resolution) - The Board of Directors proposes to amend article 5 paras. 2, 4, 5 and 6 and article 12 paras. 1 and 2 of the Articles of Association as set forth in the invitation to the Extraordinary General Meeting, provided that these amendments shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
2.1 | Election of Andrew Davis (as Chairperson and member of the Board of Directors) - The Board of Directors proposes to elect Andrew Davis as Chairperson and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
2.2 | Election of John Minardo (as member of the Board of Directors) - The Board of Directors proposes to elect John Minardo as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
2.3 | Election of Sravan Emany (as member of the Board of Directors) - The Board of Directors proposes to elect Sravan Emany as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
3.1 | Election of Andrew Davis - The Board of Directors proposes to elect Andrew Davis as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
3.2 | Election of John Minardo - The Board of Directors proposes to elect John Minardo as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
3.3 | Election of Sravan Emany - The Board of Directors proposes to elect Sravan Emany as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting). | Management | For | For | |||||
4. | Delisting of the Company's Shares (Conditional Resolution) - The Board of Directors proposes to approve the delisting of the ordinary shares of the Company from Nasdaq, subject to (i) Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting) and (ii) satisfaction of the requirements under the listing rules of the Nasdaq Stock Market, LLC. | Management | For | For |
VERTEX PHARMACEUTICALS INCORPORATED
Security | 92532F100 | Meeting Type | Annual |
Ticker Symbol | VRTX | Meeting Date | 17-May-2023 |
Record Date | 23-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Sangeeta Bhatia | Management | For | For | |||||
1.2 | Election of Director: Lloyd Carney | Management | For | For | |||||
1.3 | Election of Director: Alan Garber | Management | For | For | |||||
1.4 | Election of Director: Terrence Kearney | Management | For | For | |||||
1.5 | Election of Director: Reshma Kewalramani | Management | For | For | |||||
1.6 | Election of Director: Jeffrey Leiden | Management | For | For | |||||
1.7 | Election of Director: Diana McKenzie | Management | For | For | |||||
1.8 | Election of Director: Bruce Sachs | Management | For | For | |||||
1.9 | Election of Director: Suketu Upadhyay | Management | For | For | |||||
2. | Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2023. | Management | For | For | |||||
3. | Advisory vote to approve named executive office compensation. | Management | For | For | |||||
4. | Advisory vote on the frequency of future advisory votes on executive compensation. | Management | 1 Year | For |
VYNE THERAPEUTICS INC.
Security | 92941V209 | Meeting Type | Annual |
Ticker Symbol | VYNE | Meeting Date | 10-Aug-2022 |
Record Date | 14-Jun-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Steven Basta | For | For | |||||||
2 | Anthony Bruno | For | For | |||||||
3 | Elisabeth Sandoval | For | For | |||||||
2. | To ratify the selection by the Audit Committee of the Company's Board of Directors of Baker Tilly US, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-5 shares up to a ratio of 1-for-15 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement. | Management | For | For | ||||||
4. | To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 3. | Management | For | For |
VYNE THERAPEUTICS INC.
Security | 92941V209 | Meeting Type | Special |
Ticker Symbol | VYNE | Meeting Date | 12-Jan-2023 |
Record Date | 16-Nov-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement. | Management | For | For | |||||
2. | To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1. | Management | For | For |
WEST PHARMACEUTICAL SERVICES, INC.
Security | 955306105 | Meeting Type | Annual |
Ticker Symbol | WST | Meeting Date | 25-Apr-2023 |
Record Date | 03-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Mark A. Buthman | Management | For | For | |||||
1b. | Election of Director: William F. Feehery | Management | For | For | |||||
1c. | Election of Director: Robert F. Friel | Management | For | For | |||||
1d. | Election of Director: Eric M. Green | Management | For | For | |||||
1e. | Election of Director: Thomas W. Hofmann | Management | For | For | |||||
1f. | Election of Director: Molly E. Joseph | Management | For | For | |||||
1g. | Election of Director: Deborah L. V. Keller | Management | For | For | |||||
1h. | Election of Director: Myla P. Lai-Goldman | Management | For | For | |||||
1i. | Election of Director: Stephen H. Lockhart | Management | For | For | |||||
1j. | Election of Director: Douglas A. Michels | Management | For | For | |||||
1k. | Election of Director: Paolo Pucci | Management | For | For | |||||
2. | Advisory vote to approve named executive officer compensation. | Management | For | For | |||||
3. | To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023. | Management | For | For | |||||
4. | Advisory vote on the frequency of an advisory vote on executive compensation. | Management | 1 Year | For | |||||
5. | Shareholder proposal regarding Fair Elections. | Shareholder | For | Against |
ZAI LAB LTD
Security | 98887Q104 | Meeting Type | Annual |
Ticker Symbol | ZLAB | Meeting Date | 20-Jun-2023 |
Record Date | 20-Apr-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | THAT, Samantha (Ying) Du is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
2. | THAT, Kai-Xian Chen is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
3. | THAT, John D. Diekman is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
4. | THAT, Richard Gaynor is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
5. | THAT, Nisa Leung is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
6. | THAT, William Lis is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
7. | THAT, Scott Morrison is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
8. | THAT, Leon O. Moulder, Jr. is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
9. | THAT, Michel Vounatsos is hereby elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
10. | THAT, Peter Wirth is hereby re-elected to serve as a director until the 2024 annual general meeting | Management | For | For | |||||
11. | THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2023, respectively, is hereby approved. | Management | For | For | |||||
12. | THAT, the authority of the Board of Directors to fix the auditor compensation for 2023, is hereby approved. | Management | For | For | |||||
13. | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement, is hereby approved. | Management | For | For | |||||
14. | THAT, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 20% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved. | Management | For | For | |||||
15. | THAT, if Ordinary Resolution 14 is not approved, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 10% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved. | Management | For | For |
ZOETIS INC.
Security | 98978V103 | Meeting Type | Annual |
Ticker Symbol | ZTS | Meeting Date | 18-May-2023 |
Record Date | 24-Mar-2023 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Paul M. Bisaro | Management | For | For | |||||
1b. | Election of Director: Vanessa Broadhurst | Management | For | For | |||||
1c. | Election of Director: Frank A. D'Amelio | Management | For | For | |||||
1d. | Election of Director: Michael B. McCallister | Management | For | For | |||||
1e. | Election of Director: Gregory Norden | Management | For | For | |||||
1f. | Election of Director: Louise M. Parent | Management | For | For | |||||
1g. | Election of Director: Kristin C. Peck | Management | For | For | |||||
1h. | Election of Director: Robert W. Scully | Management | For | For | |||||
2. | Advisory vote to approve our executive compensation. | Management | For | For | |||||
3. | Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2023. | Management | For | For | |||||
4. | Approval of an amendment to our Restated Certificate of Incorporation to create a right to call a special meeting. | Management | For | For | |||||
5. | Shareholder proposal regarding ability to call a special meeting. | Shareholder | Against | For |
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Registrant) | Tekla Healthcare Investors | |||
By (Signature and Title)* | ||||
/s/ Daniel R. Omstead | ||||
(Daniel R. Omstead, President) | ||||
Date | 8/4/23 | |||
*Print the name and title of each signing officer under his or her signature.
2